Antilarval substituted phenols, distribution of tricyclic pyrones in mice, and synthesis of unnatural amino acids by Nguyen, Thi D.T.
  
ANTILARVAL SUBSTITUTED PHENOLS, DISTRIBUTION OF TRICYCLIC PYRONES  
IN MICE, AND SYNTHESIS OF UNNATURAL AMINO ACIDS 
 
 
 
by 
 
 
THI D.T. NGUYEN 
 
 
 
B.Sc., Cantho University, Vietnam, 2001 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Chemistry 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2014 
 
 
 
 
Abstract 
Three research projects were carried out and they are described below. 
The synthesis of substituted phenolic compounds including halogenated di- and 
trihydroxybenzenes, aminophenols, and substituted di-tert-butylphenols are described.  Redox 
potentials of the synthesized molecules along with various known laccase substrates were 
measured, and an inverse relationship between the oxidation potential and the efficiency of 
oxidation by laccase of halogenated hydroxybenzenes and aminophenols is demonstrated.  The 
synthesized substituted phenols were found to be substrates but not inhibitors of laccase.  We 
discovered a new class of di-tert-butylphenols compounds that inhibits the growth of mosquito 
larvae at low concentrations.  Compound 17, 2,4-di-tert-butyl-6-(3-methyl-2-butenyl) phenol 
caused greater than 98% mortality of third-instar larvae of Anopheles gambiae in the 
concentration of 0.18 µM.  These compounds do not inhibit laccases.  It appears that they affect 
a new target of the mosquito that is different from those of currently existing pesticides.   
Two anti-Alzheimer molecules, CP2 and TP70, discovered in our laboratory were studied 
for their pharmacokinetics and distribution.  The distribution of CP2 and TP70 in mouse brain 
region and various tissues of mice were examined.  HPLC analysis revealed that CP2 treatment 
in primary neurons accumulates in mitochondria fraction.  Similarly, the amount of CP2 in the 
brain tissue from wild type and APP/PS1 mice treated with 25 mg/kg/daily for 2 months also 
have the highest concentration in the mitochondria fractions in the hippocampus.  The results 
show that CP2 and TP70 can penetrate the blood brain barrier and accumulate in the tissue in 
significant amounts.  Pharmacokinetics and bioavailability of compound TP70 were determined.  
Area under the curve and bioavailability value F were calculated, and data show that TP70 has a 
good PK profile and bioavailability.   
For the preparation of a novel tripeptidyl norovirus 3C-like protease (3CL
pro
) inhibitor, 
the P3 unnatural amino acid, (S)-3-hydroxyphenylalanine was synthesized.  The P3 is designed 
to increase the polarity with the addition of the alcohol group.   After combining the P3 unnatural 
amino acid with the P1 and P2 to form the novel tripeptidyl compound, a study comparing the 
relations between the structure and its activity (SAR) will confirm whether prediction is correct 
in our pursuit for an antiviral therapeutic drug in the form of a protease inhibitor.  
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potentials of the synthesized molecules along with various known laccase substrates were 
measured, and an inverse relationship between the oxidation potential and the efficiency of 
oxidation by laccase of halogenated hydroxybenzenes and aminophenols is demonstrated.  The 
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larvae at low concentrations.  Compound 17, 2,4-di-tert-butyl-6-(3-methyl-2-butenyl) phenol 
caused greater than 98% mortality of third-instar larvae of Anopheles gambiae in the 
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Two anti-Alzheimer molecules, CP2 and TP70, discovered in our laboratory were studied 
for their pharmacokinetics and distribution.  The distribution of CP2 and TP70 in mouse brain 
region and various tissues of mice were examined.  HPLC analysis revealed that CP2 treatment 
in primary neurons accumulates in mitochondria fraction.  Similarly, the amount of CP2 in the 
brain tissue from wild type and APP/PS1 mice treated with 25 mg/kg/daily for 2 months also 
have the highest concentration in the mitochondria fractions in the hippocampus.  The results 
show that CP2 and TP70 can penetrate the blood brain barrier and accumulate in the tissue in 
significant amounts.  Pharmacokinetics and bioavailability of compound TP70 were determined.  
Area under the curve and bioavailability value F were calculated, and data show that TP70 has a 
good PK profile and bioavailability.   
For the preparation of a novel tripeptidyl norovirus 3C-like protease (3CL
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to increase the polarity with the addition of the alcohol group.   After combining the P3 unnatural 
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Chapter 1. Antilarval substituted phenols 
 
1.1  Introduction 
 
Mosquitoes are important arthropods affecting human health.  Mosquitoes transmit some 
of the deadliest diseases known to man, such as malaria, yellow fever, dengue, Ebola, etc., 
claiming many millions of lives.
1
  In fact, over 100 countries and about half of the world 
population are at risk of being infected with malaria.  This leads to about 300 - 500 million 
malaria cases and between 1 - 1.5 million people die worldwide every year.  Insecticides have 
played a significant role in public health; however, the use of insecticides for mosquito control is 
in jeopardy.  Currently, pyrethroids are the primary insecticides used for mosquito control, and 
resistance to this class of compounds develops rapidly in the mosquitoes.  These facts clearly 
prove that malaria is an especially serious problem and it is urgent to develop new insecticides 
that have novel targets to combat the transmission of malaria.  
 
Laccases, copper-containing oxidases, are important enzymes found in many species of 
bacteria, fungus, plants and insects, and are utilized in a variety of ways depending on the 
species.
2
  In plants, for example, tissues undergoing lignin synthesis express high levels of the 
laccase gene, and laccase is also believed to be used by plants to detoxify environmental 
pollutants affecting the plants.
3,4
  Fungal laccase, on the other hand, involves in lignin 
degradation as seen in white rot fungi.
5,6
  Our research focuses on insect laccases, particularly in 
the malaria transmitted mosquito, Anopheles gambie.  Laccase is an important enzyme involving 
in the formation of external insect cuticle.
7-9
  The formation of the cuticle, including 
sclerotization or tanning, is essential to insect survival because it protects insect from the 
environment and is involved in other key processes such as communication, locomotion, and 
respiration.  Therefore, it is vital to understand the laccase enzyme as it might serve as an 
important target for controlling insect populations, especially the malaria mosquito, Anopheles 
gambiae. 
 2 
 
As a class, laccases are glycoproteins that typically contain multiple copper atoms at the 
enzyme’s active site.  Laccases are oxidoreductases that reduce oxygen to water while oxidizing 
various organic compounds, particularly substituted o-, m-, and p-phenols, polyphenols,  
aromatic amines and N-hydroxamines.
10-13
.  However, laccase inhibitors are rare and few useful 
organic compounds have been found.
14-16
  Ideal compounds would bind irreversibly to the 
enzyme’s active site, effectively cross-linking the enzyme.  Other compounds, that serve as 
competitive substrates might also be good inhibitors, but are not ideal because the enzyme 
eventually regains activity.   
 
The goals of this work were to synthesize classes of halogenated polyphenols, substituted 
aminophenols, and di-tert-butyl substituted phenols, and study their redox potentials, laccase 
activities, and mosquito larval inhibitory activities.  The results may shed light onto future design 
of environmentally compatible laccase inhibitors and mosquito larvicides.  The synthesis of these 
compounds was done by Dr. Keshar Prasain and me.  The redox potentials of these compounds 
were measured by me using the facilities in Dr. Jun Li’s laboratory.  The laccase substrate 
activities were measured by Dr. Maureen Gorman and Zeyu Peng in Dr. Michael Kanost’s 
laboratory, Kansas State University and the anti-mosquito larval activities were studied in Dr. 
Kun Yan Zhu’s laboratory, Kansas State University.  Since the biological works were performed 
in other laboratories, limited discussions are described in this thesis.  
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1.2  Background 
 
Laccases are typically monomeric extracellular enzymes containing four copper atoms 
per monomer bound to three redox sites designated as T1, T2 and T3.
5
  These coppers can be 
differentiated by UV/Vis and electronic paramagnetic resonance.  The trinuclear cluster 
(containing one Cu T2 and two Cu’s T3) is located approximately 12 Å away from the T1 site, 
and it is the place where molecular oxygen is reduced to water.  Type I copper is the site where 
substrate oxidation takes place due to its high redox potential of around +790 mV.
17-18
  In fungal 
laccase, T1 copper exhibits a planar trigonal geometry by coordinating with one cysteine and  
imidazole side chains of two histidines through sulfur and nitrogen atoms respectively.  One T2 
and two T3 copper atoms are arranged in a trinuclear cluster and coordinated to two and six 
histidines residues, respectively (Figure 1.1).
3 
 The electrons from the T1 copper site are 
transferred through the highly conserved His-Cys-His tripeptide to the T2/T3 copper trinuclear 
cluster, where four-electron reduction of molecular oxygen to water takes place.
12
   
  
 
Figure  1.1  Schematic representation of tricopper site in fungal laccase.3,12 
 
 
 
 
 
 4 
The typical reaction of laccase is oxidation of a phenolic compound with the concurrent 
reduction of molecular oxygen to water.  After four cycles of single-electron oxidations forming 
free radicals, the enzyme reduces one molecule of oxygen, generating two molecules of water 
(Figure 1.2).  The unstable radical may undergo further laccase-catalyzed oxidation or non-
enzymatic reactions such as hydration and polymerization or couple to other phenolic 
structures.
44 
 
 
Figure ‎1.2  Schematic representation of oxidation of phenolic substrates (hydroquinone) to 1,4-
benzoquinone and reduction of molecular oxygen to water by laccase.  
 
Laccases can be strongly inhibited by various reagents with IC50 values in the high 
concentrations (mM ranges).  Small anions such as azide, halides, cyanide, thiocyanide, fluoride 
and hydroxide bind to the type 2 and type 3 trinuclear copper sites, resulting in an interruption of 
the internal electron transfer and inhibition of activity.  Smaller sized and low electronegativity 
halides inhibit laccases more effectively than those latter in the periodic table (fluoride > chloride 
> bromide).  Other inhibitions include metal ions, fatty acids, hydroxylglycine, kojic acid by 
causing amino acid residue changes, conformational changes or copper chelation.
14, 34, 41-43 
 
The cuticle of insects, also known as exoskeleton of the insect, is mainly composed of 
chitin, protein, and catecholamine derivatives.
19
  Insect cuticle does not expand readily and 
continuously; as a result, insects must often shed their old cuticle and make a new cuticle for 
growth.  The newly formed cuticle is usually soft and pale, and soon it becomes hard and tanned 
by a process known as sclerotization.  Sclerotization also aids the hardening of the pupal cuticle 
and protects the pupae during larval-pupal transformation.  Disruption of sclerotization can lead 
to the death of insects because without sclerotization the organism would be vulnerable to its 
environmental enemies and die from desiccation.  In cuticular sclerotization, two types of phenol 
 5 
oxidases present in the cuticle, tyrosinases or laccases catalyze oxidation N-acetyl 
catecholamines to highly reactive quinones followed by reacting with nucleophilic side chains of 
histidines and other amino acids of cuticular proteins to form the inter-protein cross linking and 
polymer as shown in Figure 1.3.
8
  This formation play a major role in strengthening and 
stabilization the cuticle.  In 2005 and 2009, Arakane et al.
9,20
 using the RNA interference 
experiments demonstrated the importance of laccase 2 not only for hardening of the cuticle but 
proper morphology and pigmentation as well.  Reducing the level of laccase 2 (TcLac2) in the 
red flour beetle Tribolium castaneum resulted in insects failed to tan normally and physical 
deformities.  These phenomena were also observed at the larval, pupa, and adult stages causing 
death within days of molting. 
 
 
Figure ‎1.3  Proposed protein cross-linking during cuticle sclerotization in pupa of Manduca 
sexta.
8
  The figure is copied from Karmer et al. Tetrahedron 2001, 57, 385-392 without 
permission. 
 6 
1.3  Results and discussion 
 
1.3.1  Synthesis and redox potential of halogenated phenols and amino phenols. 
 
Laccase is known to be an important enzyme in insect cuticle sclerotization, it might 
serve as an important target for controlling insect populations, especially the malaria mosquito, 
Anopheles gambiae.  With this in mind, our initial plan was to discover, design, and synthesize 
novel chemicals which can be laccase inhibitors and may lead to the inhibition of mosquito 
laccase.  Halides are known to inhibit laccases at the Type 2/3 trinuclear copper site, hence 
compounds 1 - 6 were incorporated a leaving group such as chlorine (compound 1 – 2) or both 
bromine and chlorine (compound 3 – 6).  To examine the activity of different positional isomers, 
compounds 3 – 5 have the hydroxyl groups oriented towards ortho, para and meta positions, 
respectively.  Compound 6 (triol) having both ortho and para oriented hydroxyl groups was 
expected to have the highest laccase activity among the synthesized halogen substituted phenols.    
In addition, it has been reported that the introduction of methoxy group in phenolic compounds 
increases their laccase oxidative activity
21
; therefore, the presence of methoxy group in 
compound 1, 3 - 5 might enhance their laccase oxidative activity.  The amino function of 
synthesized o-aminophenols 7
22
 and 8
23
 were investigated since the resulting iminoquinones 
might complex with the copper in the laccase binding site (T1 site) and upon laccase oxidation 
would produce more reactive iminoquinones than the quinone analogs.  The nucleophilic 
moieties like amino or hydroxyl function present in the laccase protein close to the T1 copper 
site might add irreversibly to the iminoquinone producing a covalently linked adduct and inhibit 
laccase activity.
24-25
  With these ideas in mind, various halogen containing phenols and 
polyphenols, and aminophenols, were synthesized (Figure 1.4).
33
  Synthesis of compound 1 has 
been previously reported by Dr. Hua’s laboratory.26 
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Figure  1.4  Synthesized halogenated polyphenols, and aminophenols. 
 
1.3.1.1  Syntheses of compounds 2 and 3. 
 
The synthetic route of 3-chloro-4,5-dihydroxybenzaldehyde (2) and 4-bromo-3-chloro-5-
methoxybenzene-1,2-diol (3)  is outlined in Scheme 1.1.  
 8 
Scheme ‎1.1  Syntheses of compound 2 and 3. 
 
 
 
 Compound 2 was obtained in 86% yield by demethylation of 3-chlorovanillin (1) with 
boron tribromide (BBr3) in CH2Cl2 at 0
o
C for 30 minutes and 25
o
C for 12 hours. The two 
hydroxyl functions on C-4 and C-5 positions of compound 2 were then protected by the use of 
tert-butyldimethylsilyl chloride, triethylamine, and 4-dimethylaminopyridinene (DMAP) in 
CH2Cl2 at 0
o
C for 1 hour and 25
o
C for 3 hours to give 3,4-bis(tert-butyldimethylsilyloxy)-5-
chlorobenzaldehyde (24) in 79% yield. Compound 24 on Baeyer-Villiger oxidation using m-
chloroperbenzoic acid (MCPBA) (70% pure) in CH2Cl2 under reflux for 10 hours afforded 3,4-
bis(tert-butyldimethylsilyloxy)-5-chlorophenyl formate (25) in 79% yield.  Basic methanolysis 
of formate 25 was carried out with K2CO3 in methanol at 25
o
C for 12 hours to give 3,4-bis(tert-
butyldimethylsilyloxy)-5-chlorophenol (26) in 87% yield.  The less hindered C-2 position of 
compound 26 was regioselectively brominated by the use of N-bromosuccinimide (NBS) in 
dimethylformamide (DMF) for 22 hours to give  2-bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-
chlorophenol (27) in 63% yield; based on recovered starting material.  Methylation of the 
phenolic hydroxyl moiety in compound 27 was achieved by the use of trimethyloxonium 
 9 
tetrafluoroborate (Me3O•BF4) in the presence of proton sponge in CH2Cl2 at 0
o
C for 8 hours to 
give 2-bromo-4,5-bis-(tert-butyldimethylsilyloxy)-3-chloro-1-methoxybenzene (28) in 95% 
yield.  Finally, the desired compound 3 was obtained by the desilylation of compound 28 with 
tetra-n-butylammonium fluoride (TBAF) in THF at 0
o
C for 30 minutes in 71% yield.  
 
1.3.1.2 Synthesis of compound 4. 
 
2-Bromo-3-chloro-5-methoxy-1,4-dihydroxybenzene (4) was synthesized from aldehyde 
1
26
 following a sequence of reactions as outlined in Scheme 1.2.  
 
Protection of the hydroxyl function of 1 by using tert-butyldimethylsilyl chloride in the 
presence of triethylamine and DMAP in CH2Cl2 at 25
o
C for 12 hours gave 4-(tert-
butyldimethylsilyloxy)-3-chloro-5-methoxybenzaldehyde (20) in 85% yield.  Baeyer-Villiger 
oxidation of compound 20 with the use of MCPBA in CH2Cl2 under reflux for 8 hours gave 4-
(tert-butyldimethylsilyloxy-3-chloro-5-methoxyphenyl formate (21) along with the hydrolyzed 
product 4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (22) in the yield of 63% and 
27%, respectively.  The formate function of compound 21 was hydrolyzed to the phenolic 
function by basic methanolysis using potassium carbonate (K2CO3) in methanol at 25
o
C for 4 
hours to give phenol 22 in 90% yield.  The less hindered C-2 position in compound 22 was 
regioselectively brominated by the use of NBS in DMF at room temperature for 12 hours 
following the literature published by Hua’s group in the total synthesis of (+)-
chloropuupehenone.
26
  However, bromination of compound 22 under NBS condition gave 2-
bromo-3-chloro-5-methoxy-1,4-benzoquinone (19) along with the desilylated product 2-bromo-
4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (23) in 48% and 31% yield, 
respectively.  Compound 19 might have formed by the hydrolytic cleavage of silyl ether 23 by 
the HBr generated from the action of NBS and trace amount of water in the reaction mixture 
followed by the oxidation to the quinone.  NBS oxidation of dihydroquinone to benzoquinone 
has been previously reported by Barakat et al.
27
  Interestingly, deprotection of compound 23 by 
the use of TBAF in THF at 0
o
C for 30 minutes gave quinone 19 in 81% yield.  Reduction of 
compound 19 in presence of 10% palladium/carbon in ethanol under hydrogen (1 atm.) at 25
o
C 
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for 15 minutes afforded the desired compound 4 in 100% yield.  Infrared spectrum of compound 
19 does not show a characteristic hydroxyl stretch but shows a quinone stretch at 1683 cm
-1
, 
whereas compound 4 shows hydroxyl absorption at 3303 cm
-1
 implying compounds 19 and 4 are 
quinone and dihydroquinone, respectively.  
 
Scheme  1.2  Synthesis of compound 4. 
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1.3.1.3 Synthesis of compound 5.  
 
 The synthesis of 4-bromo-5-chloro-6-methoxybenzene-1,3-diol (5) is outlined in Scheme 
1.3.  Selective protection of hydroxyl moiety on C-5 position of compound 2 was achieved by 
the use of equivalent amount of tert-butyldimethylsilyl chloride in the presence of triethylamine 
and DMAP in CH2Cl2 at 25
o
C for 8 h to give 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
hydroxybenzaldehyde (29) and compound 24 (with both protected hydroxyl groups) in 70% and 
11% yield, respectively.  The structure of compound 29 was confirmed by a single-crystal X-ray 
analysis as shown in Figure 1.5.  The less hindered C-5 hydroxyl moiety in compound 2 is likely 
to react faster with tert-butyldimethylsilyl chloride than the more hindered C-4 hydroxyl moiety 
giving compound 29 predominantly.  Methylation of the  phenolic hydroxyl moiety in compound 
29 was achieved by the treatment with trimethyloxonium tetrafluoroborate and proton sponge in 
CH2Cl2 at 0
o
C for 8 hours to give 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
methoxybenzaldehyde (30) in 78% yield; based on the recovery of starting material 29.  
Compound 30 on Baeyer-Villiger oxidation by the use of MCPBA (70% pure) in CH2Cl2 under 
reflux for 12 hours afforded 3,4-bis(tert-butyldimethylsilyloxy)-5-chloro-4-methoxyphenyl 
formate (31) along with the hydrolyzed product 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
methoxyphenol (32)  in 42%  and 44% yield, respectively.  Basic methanolysis of the formate 
function in compound 31 with K2CO3 in methanol at 25
o
C for 12 hours afforded phenol 32 in 
quantitative yield. Regioselective bromination on the less hindered C-2 position of compound 32 
was achieved by the use of NBS in DMF for 12 hours giving 2-bromo-5-(tert-
butyldimethylsilyloxy)-3-chloro-4-methoxyphenol (33) in 67% yield.  Finally, desilylation of 
compound 33 by treating with TBAF in THF at 0 
o
C for 30 minutes led to the formation of 
desired product 5 in 60% yield. 
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Scheme  1.3  Synthesis of compound 5. 
 
 
 
Figure ‎1.5  Crystal structure of compound 29. 
 13 
1.3.1.4  Synthesis of compound 6. 
 
5-Bromo-6-chlorobenzene-1,2,4-triol (6) was synthesized from 4-bromo-3-chloro-1,2-
dibenzyloxy-5-(tert-butyldimethylsiloxy)benzene (34), an intermediate previously reported by 
Hua’s lab in the synthesis of (+)-chloropuupehenone,26 in two steps as outlined in Scheme 1.4.  
 
Scheme  1.4  Synthesis of compound 6. 
 
 
 
Desilylation of 34 by the use of TBAF in THF at 0
o
C for 1 hour afforded 2-bromo-3-
chloro-4,5-dibenzyloxyphenol (35) in 74% yield.  Finally, removal of two benzyl groups in 
compound 35 by catalytic hydrogenation (H2, 1 atm.) in the presence of 10% palladium/carbon 
in ethanol at 25
o
C for 3 hours gave 6 as the desired product in 93 % yield.  The infrared spectrum 
of triol 6 shows strong hydroxyl absorption at 3382 cm
-1
.  Triol 6 upon standing in air produced a 
black solid which might have resulted from its air oxidation to quinone followed by 
decomposition.  Hence, triol 6 was immediately stored in a dry box under nitrogen atmosphere 
and used as soon as possible for the laccase activity study. 
 
1.3.1.5  Syntheses of aminophenols 7 and 8. 
 
 A reaction for the selective reduction of the nitro function in 4-hydroxy-3-
nitrobenzaldehyde (36) by the use of iron in the presence of acetic acid led to the formation of a 
mixture of several compounds, as indicated by TLC analysis, which could not be separated and 
analyzed.  However, catalytic hydrogenation of 4-hydroxy-3-nitrobenzaldehyde by the use of a 
catalytic amount of palladium/carbon under 30 psi of hydrogen in ethanol for 4 hours gave 2-
amino-4-(hydroxymethyl)phenol (7)
22
 and 2-amino-4-methylphenol (8)
23
 each with 41% yield as 
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shown in Scheme 1.5.  The products were formed by the reduction of both nitro and aldehyde 
functions of 4-hydroxy-3-nitrobenzaldehyde.  Compound  8 is formed by further reduction of 
benzylic hydroxyl function in compound 7 under hydrogenation condition.  No reaction was 
observed when the catalytic hydrogenation of 36 was carried out in the presence of Raney Nickel 
under similar reaction conditions.   
 
Scheme  1.5  Syntheses of compound 7
22
 and 8
23
. 
 
 
 
Laccase oxidation activity of compounds 1 – 8 along with known laccase substrates  such 
as hydroquinone, catechol, 2-aminophenol, 1,2-diphenyleneamine,  and ABTS  were tested with 
fungal laccase Tramestes versicolor.  This study was carried by Dr. Maureen Gorman and Zeyu 
Peng in Dr. Michael Kanost’s laboratory and results have been published.33  The known laccase 
substrates were used as positive control for comparison.  In summary, the results showed that 
these halogenated phenols and amino phenols were not laccase inhibitors; however, the laccase 
oxidation efficiency of most of the synthesized polyphenols and aminophenones were found to 
be higher than that of known substrates indicating their role as better laccase substrates.   
 
After knowing that synthesized  halogenated phenols and amino phenols (compounds  1 – 
8) were not laccase inhibitors but may serve as laccase substrates, the electrochemical properties 
of these compounds were investigated to better understand the oxidation ability of these 
compounds.  Therefore, cyclic voltammetry (CV) experiments were carried out to study the 
redox properties of compounds 1 – 8 and other known laccase substrates ( Figure 1.6) like 
hydroquinone, catechol, 2-aminophenol, 1,2-phenylenediamine, and 2,2’-azino-bis-(3-
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ethylbenzothiazoline-6-sulfonic acid) (ABTS), 3-amino-4-hydroxybenzoic acid (44) and 4-
amino-3-hydroxybenzoic acid (45) which were used as positive control in the experiment.   
 
 
Figure  1.6  Known laccase substrates used in CV experiments. 
 
Most of the synthesized polyphenols and aminophenones having lower or similar values 
of oxidation peak potential (Epa) as that of known substrates could be easily oxidized by laccase.   
Different positions of two hydroxy groups in the benzene rings are responsible for different rates 
of their oxidation.  Since the ease of oxidation of dihydroxybenzenes is para (dihydroquinone) > 
ortho (catechol) > meta (resorcinol),
 37-38
 dihydroxyquinone (4) had lower redox potential as 
compared to catechols 2 and 3.  Moreover, resorcinol 5 was found to have highest redox 
potential among the polyphenols.  As expected, triol 6 was found to have the lowest oxidation 
potential (80 mV) thus gives the highest laccase activity.  An inverse relationship between 
laccase oxidation efficiency (Kcat/Km) and redox potential of studied compounds including 
compounds 1 – 8, 44, 45, ABTS, 2-aminophenol, catechol, hydroquinone, and 1,2-
phenylenediamine is highlighted in Figure 1.7.  These results are in agreement with previous 
studies which showed that the higher the oxidation potential, the lower laccase oxidation 
efficiency is.
34-36
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Figure ‎1.7  Correlation of laccase activities and redox potentials of compounds 1 – 8, 44, 45, 
ABTS, 2-aminophenol, catechol, hydroquinone, and 1,2-phenylenediamine. 
Epa : oxidation peak potential (Volt) 
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1.3.2  Synthesis and anti-mosquitoes larval activity of substituted di-tert-butyl phenols. 
After failing in synthesizing a class of laccase inhibitors (compounds 1 – 8), our research 
efforts focus on searching for new anti-larval agents which have a different target in controlling 
mosquitoes.  In insect, juvenile hormone refers to a group of hormone, secreted from a pair of 
glands behind the brain, that promotes the growth of larva while preventing metamorphosis.  The 
juvenile hormone inhibits development of adult characteristics until the insects reach a proper 
stage.  Juvenile hormones also play a prominent role for the production of eggs in female insects 
and in regulating reproductive maturation in adult insects.  Therefore, synthetic juvenile hormone 
mimics have been widely used as pesticides for mosquito controls since they can cause 
premature molting of young immature stages, disrupting larval development.  MON-0585 (9, 
Figure 1.8), developed by Monsanto, is a juvenile hormone mimic and implicated as insect 
growth regulators.
28 
 MON-0585 is also known to affect cuticle sclerotization in mosquitoes.
29  
 
To investigate how the nature of the phenyl group on the side chain of MON-0585 affects 
activity, we started by changing it into different functional groups such as alcohol, aldehyde, 
carboxylic acid and oxime analogs (compound  11 – 15, Figure 1.9).33 
 
 
Figure  1.8  Chemical structure of MON-0585 (9). 
 
 
Figure ‎1.9  Synthesized substituted di-tert-butyl phenols (compounds 11 - 15). 
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Several 2,6-di-tert-butyl phenols 11 – 15 were synthesized mimicking the structure of 
MON-0585 as outlined in Scheme 1.6. 
 
Scheme  1.6  Synthesis of compound 11 – 15. 
 
 
Following the reported procedure,
30 
 Friedel-Craft acylation of 2,6-di-tert-butylphenol 
(37) with isobutyryl chloride (38) in the presence of anhydrous aluminum chloride (AlCl3) at -
10
o
C for 15 minutes gave compound 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-
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one (10) in 90% yield.  Bromination of compound 10 with cupric bromide in a solvent mixture of 
dichloromethane and ethyl acetate for 3 h afforded 2-bromo-1-(3,5-di-tert-butyl-4-
hydroxyphenyl)-2-methylpropan-1-one (11) in 96% yield which on further treatment with excess 
of lithium aluminum hydride (LiAlH4) in dry diethyl ether under reflux for 3 h gave 2,6-di-tert-
butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol (12) in 100% yield.  Compound 12 is likely 
formed by the hydride attack on the carbonyl carbon followed by aryl group rearrangement 
(Scheme 1.7).
31
 The para-hydroxyl group facilitates the 1,2-shift of aryl group in the epoxide 
intermediate 11a. 
 
Scheme  1.7  Proposed mechanism for the formation of 12. 
 
 
Compound 12 on oxidation with o-iodoxybenzoic acid (IBX) in dimethyl sulfoxide 
(DMSO) for 12 hours furnished 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal (13) in 
99% yield. Aldehyde 13 was further oxidized to 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-
methylpropanoic acid (14)
32
 in 82% yield by treating with silver oxide, prepared in situ by 
reacting silver nitrate (AgNO3) and sodium hydroxide (NaOH) in the solvent mixture of water 
and 1,4-dioxane at 25
o
C for 12 hours.  Treatment of aldehyde 13 with hydroxylamine 
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hydrochloride and sodium acetate in a solvent mixture of acetonitrile and water (2:1) for 1.5 hour 
gave (E)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime (15) in 97% yield.   
The next goal was to synthesize amine from the oxime 15; however, the oxime 15 could 
not be reduced to its corresponding amine on a catalytic hydrogenation by the use of 10% 
palladium/carbon in ethanol under 30 psi of hydrogen for 16 hours (Scheme 1.8).  Therefore, 
reductive amination of aldehyde 13 was carried out by the use of benzylamine in toluene under 
reflux conditions for 12 hours followed by the removal of toluene under rotovapor and addition 
of methanol and sodium cyanoborohydride (NaBH3CN) to give 4-(1-(benzylamino)-2-
methylpropan-2-yl)-2,6-di-tert-butylphenol (16) in 97% yield.  The removal of benzyl group in 
compound 16 leading to the corresponding amine was not achieved under catalytic 
hydrogenation conditions by the use of hydrogen (30 psi) in the presence of 10% 
palladium/carbon in ethanol for 12 hours.  Moreover, increasing the temperature to 50
o
C had no 
effect on the reaction and resulted in the recovery of the starting material.  Changing the catalyst 
to platinum oxide (PtO2) also failed in the removal of benzyl group.    
 
Scheme  1.8  Synthesis of compound 16. 
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In addition to the 2,6-di-tert-butyl phenolic compounds, synthesis of 2,4-di-tert-butyl-6-
(2-methylbut-3-en-2-yl)phenol (41) was envisioned by following Friedel-Crafts alkylation of 
2,4-di-tert-butyl phenol (39) and 2-methyl-3-buten-2-ol (40) as highlighted in Scheme 1.9a.  
Compound 41 would have all the major structural features of MON-0585; moreover, would have 
an additional side chain with a terminal double bond that could be manipulated into different 
functional groups as desired.  However, instead of giving compound 41, treatment of 2,4-di-tert-
butylphenol with 2-methyl-3-buten-2-ol in the presence of boron trifluoride.ether (BF3•O(Et)2) in 
CH2Cl2 at 25
o
C for 1 hour afforded 2,4-di-tert-butyl-6-(3-methyl-2-butenyl)phenol (17) and 6,8-
di-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromene (18) in 46% and 10% yield respectively.  
Benzopyran 18 appears to be derived from an acid-catalyzed ring closing reaction of compound 
17 as highlighted in Scheme 1.9b. 
 
Scheme  1.9  a) Syntheses of compound 17 and 18 and b) proposed mechanism for the formation 
of 18. 
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MON-0585 (9) was used as a positive control and was prepared by a Friedel-Crafts 
alkylation reaction of 4-cumylphenol (42) and isobutylene (43) in the presence of catalytic 
amount of sulfuric acid in dichloroethane in a sealed tube at 80
o
C for 6 h as shown in Scheme 
1.10.
39
  
 
Scheme  1.10  Synthesis of MON-0585. 
 
 
Substituted di-tert-butyl phenolic compounds 10 - 16, benzopyran 17, and MON-0585 
were not oxidized by laccase and their laccase activity could not be detected due to their water 
insolubility.  Cyclic voltammetry (CV) experiments were carried out to study the redox 
properties of compounds 10 - 17, MON-0585 (9), including other known laccase substrates like 
hydroquinone, catechol, 2-aminophenol, 1,2-phenylenediamine, and 2,2’-azino-bis-(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS), 3-amino-4-hydroxybenzoic acid (44) and 4-
amino-3-hydroxybenzoic acid (45).   These compounds show only one of the redox waves and 
have broad peak separation (> 540 mV).  These compounds caused unreliable CV measurements 
due to their most water-insoluble property in the phosphate-buffered saline (PBS) solution 
containing 20% ethanol.  
 
Laccase are used as the building blocks in the insect cuticle sclerotization.  Therefore, 
laccase substrates such as triol 6,  MON-0585 (9), dihydroquinone, and various di-tert-butyl 
phenolic compounds including compound 10 - 16, and di-tert-butyl substituted benzopyran 17 
were investigated for their anti-larval activities by using the third-instar larvae of Anopheles 
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gambiae in a three-day bioassay.  MON-0585 known as an insect growth regulator was used as a 
positive control and for comparison.  This study was performed in Dr. Kun Yan Zhu’s laboratory 
at Kansas State University by him and his assistant and the result has been published.
33
   For the 
anti-larval assay, water soluble compounds like hydroquinone and triol 6 were dissolved in water 
and used; whereas water-insoluble compounds such as di-tert-butyl phenol derivatives 10 - 16 
and benzopyran 17 were first dissolved in acetone and used for the assay in aqueous solution.  
The larval toxicity studies were investigated for two concentrations per compound; 50 and 1000 
µg/mL.   
 
Table  1.1  Toxicities of substituted phenols to third-instar larvae of Anopheles gambiae in a 
three-day bioassay.
33
 
 
Compound  % Mortality (mean ± SE) 
50‎μg/L‎ 1000‎μg/L‎ 
Control 
Dihydroquinone 
MON-0585 (9) 
Compound 6 
Compound 11 
Compound 12 
Compound 13 
Compound 14 
Compound 15 
Compound 16 
Compound 17 
Compound 18 
 
0 ± 0b 
1.25 ± 1.25 b 
93.3 ± 4.71 a 
0 ± 0b 
0 ± 0b 
0 ± 0b 
0 ± 0b 
5.50 ± 3.455 b 
5.41 ± 3.28 b 
3.71 ± 2.14 b 
98.1 ± 1.93 b 
5.77 ± 3.69 b 
 
3.50 ± 3.50 d 
5.38 ± 1.80 d 
100 ± 0 a 
11.4 ± 3.85 d 
60.0 ± 11.5 c 
46.7 ± 3.25 c 
65.0 ± 5.00 c 
12.3 ± 1.35 d 
93.1 ± 3.99 ab 
7.70 ± 3.14 d 
98.3 ± 1.68 ab 
91.7 ± 6.31 d 
 
 
Results are mean ± standard errors (SE) of four replicates (n = 4); each with 12 – 15 third-instar 
larvae. Means followed by the same letter in the same column are not significantly different (P 
>0.05) according to Fisher’s LSD multiple comparison test after arcsine square root 
transformation of the percentage date (ProStat; PolySoftware International, 2002).
33 
 
Water soluble laccase substrates such as compound 6, compound 14 and 16 (used as a 
sodium salt and trifluoroacetic acid salt respectively) and dihydroquinone did not produce any 
toxicity at the studied concentrations.  In contrast, water-insoluble materials such as di-tert-butyl 
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phenolic compounds (11 – 13) showed more that 46% mortality of larvae at 1000 µg/mL 
concentration.  Interestingly, compound 17 was found to have similar toxicity towards the larvae 
as compared to MON-0585 at both studied concentrations.  Compound 17 appears to have higher 
toxicity than methoprene (Figure 1.10), an insect growth regulator mimicking natural juvenile 
hormone of insects and commonly used insecticides, which caused only 60% mortality at 100 
μg/L in 3 days bioassay against the third-instar larvae of Culex molestus.40  Compound 15 and 
benzopyrane 17 also produced significant toxicity to the mosquito larvae with mortality of 93% 
and 91% at the concentration of 1000 µg/mL.  Only water insoluble compounds were found to be 
toxic to the larvae suggesting that these compounds may be absorbed through the body of the 
larvae resulting in its death.  The mosquito has four distinct stages in its life cycle: egg, larva, 
pupa, and adult.  The larvae treated with di-tert-butyl phenolic compounds died just before 
pupation and over the course of 3 days indicating that the target does not involve the 
neurological system, a common target of most insecticides.  
 
 
 
Figure  1.10  Chemical structure of methoprene. 
 
To better understand what causes the death of larvae when treating with our compounds, 
the microscopic sections of the larvae killed by most active compound 17 were compared with 
that of untreated larvae (Figure 1.11).  The larva needs to remove its old cuticle and form a new 
one to grow up.  Interestingly, the larvae treated with compound 17 had thin cuticle and appeared 
to start molting; however, failed to remove the old cuticle.  Moreover, the larvae treated with 
compound 17 showed very little synthesis of new pupal cuticle as compared to the untreated 
larvae.  This phenomenon not only happens in the head of the larva but also in the thorax and 
abdomen.  This indicates that compound 15, other toxic di-tert-butyl phenolic derivatives and 
compound 17 might attack the target related to the insect cuticle formation.  However, the target 
and mechanism of action of these water insoluble di-tert-butyl phenolic compounds and 
benzopyran 17 remain to be investigated. 
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Figure  1.11  Microscopic slides of larvae of Anopheles gambiae treated and untreated with 
compound 16.
33
 A. Head of treated Larva (100X).  B. Head of treated Larva (400X).  C. Head of 
control Larva (100X).  D. Head of control Larva (400X).   
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1.4 Conclusion 
 
A new class of phenolic compounds containing halide, hydroxyl, aldehyde, methoxy, 
amino, and di-tert-butyl functions were synthesized and their redox potential, laccase oxidation, 
and mosquito anti-larval activities were examined.  Synthesized phenolic compounds 1 - 8 were 
found to be laccase substrates but not the inhibitors of laccase. Redox potentials of the 
synthesized molecules along with various known substrates were measured, and the relationship 
with the efficiency of oxidation by laccase is analyzed.  Compounds 15 and 17 were found to 
have potent anti-larval activity at low concentrations.  Treatment of 50 µg/L (or 0.18 µM) of 
compound 17 to third-instar larvae of Anopheles gambiae caused greater than 98% mortality.  It 
appears that these compounds affect a new target of the mosquito that is different from those of 
currently existing pesticides. 
1.5  Experimental section 
 
General Methods 
 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity plus 400 
MHz or 200 MHz spectrometer for 
1
H and 
13
C in deuteriochloroform (CDCl3), unless otherwise 
indicated. Tetramethylsilane was used as the internal reference and the data reported in ppm. 
Infrared (IR) spectra were recorded on a Nicolet 380 FT-IR and are reported in wavenumbers 
(cm
-1
).  Low-resolution mass spectra were taken from an API 2000-triple quadrupole ESI-
MS/MS mass spectrometer (from Applied Biosystems).  High-resolution Mass spectra were 
recorded on LCT Premier (Waters corp., Milford MA), a time of flight mass analyzer with an 
electrospray ion source.  Column chromatography was carried out on silica gel (200 – 400 mesh) 
from the University of Kansas. Tetrahydrofuran (THF) and diethyl ether were distilled over 
sodium and benzophenone, methylene chloride was distilled over calcium hydride (CaH2), and 
toluene was distilled over LiAlH4 prior for usage.  The purity of compounds, 1 - 17 and MON 
0585 were found to be ~ 98% as indicated by HPLC analysis carried on Varian Prostar 210 with 
a UV-Vis detector and a reverse phase column from Phonomenex (250 x 21.20 mm, 10 micron).  
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Experimental section for synthesis 
 
4-(tert-Butyldimethylsilyloxy)-3-chloro-5-methoxybenzaldehyde (20) 
 
 
   
To a solution of 0.40 g (2.15 mmol) of 3-chloro-4-hydroxy-5-methoxybenzaldehyde (1)
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in 5 mL of dichloromethane at 0
o
C under argon, were added 0.6 mL (4.3 mmol) of triethylamine, 
40 mg (0.33 mmol) of 4-dimethylaminopyridine (DMAP), and 0.65 g (4.3 mmol) of tert-
butyldimethylsilyl chloride and the solution was stirred at 25
o
C for 12 hours.  The reaction was 
diluted with 100 mL of diethyl ether and washed with 20 mL of saturated aqueous NH4Cl 
solution, 20 mL of water, and 20 mL of brine. The organic layer was dried over anhydrous 
MgSO4, concentrated, and the crude product was column chromatographed on silica gel using a 
mixture of hexane and diethyl ether (4:1) as eluent to give 0.55 g of  20 in 85% yield. 
1H NMR δ 
9.76 (s, 1 H), 7.45 (d, J = 2.0 Hz, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 3.85 (s, 3 H), 1.01 (s, 9 H), 0.21 
(s, 6 H); 
13C NMR δ 190.0, 151.9, 147.7, 130.0, 126.6, 126.3, 108.4, 55.6, 25.8 (3 C), 19.0, -3.8 
(2 C); HRMS calcd for C14H22ClO3Si (M+H
+
) 301.1021, found 301.1028. 
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4-(tert-Butyldimethylsilyloxy)-3-chloro-5-methoxyphenyl formate (21) & 4-(tert-
butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (22)  
 
 
   
To a solution of 0.60 g (2 mmol) of  20 in 5 mL of dichloromethane at 0
o
C under argon, 
was added 0.75 g  (3 mmol) of m-chloroperbenzoic acid (70% pure) and heated to reflux for 8 
hours.  The reaction was cooled to room temperature and 5 mL of aqueous sodium thiosulfate 
and 200 mL of diethyl ether were added to it.  The solution was washed with 20 mL of saturated 
aqueous NaHCO3, 20 mL of water, and 20 mL of brine. The organic layer was dried over 
anhydrous MgSO4, concentrated, and column chromatographed on silica gel using a mixture of 
hexane and diethyl ether (5:1) as an eluent to give 0.40 g of 21 and 150 mg of 22 in 63% and 
27% yield, respectively.  Formate 21:  
1H NMR δ 8.26 (s, 1H, OCHO), 6.78 (d, J = 2.9 Hz, 1 
H), 6.58 (d, J = 2.9 Hz, 1 H), 3.80 (s, 3 H), 1.03 (s, 9 H), 0.20 (s, 6 H); 
13C NMR δ 159.3, 151.8, 
143.2, 140.4, 125.9, 114.4, 104.1, 55.7, 26.0, 19.0, -3.9; HRMS calcd for C14H22ClO4Si (M+H
+
) 
317.0976, found 317.0968.  Phenol 22: 
 1H NMR δ 6.43 (d, J = 2.9 Hz, 1 H), 6.32 (d, J = 2.9 Hz, 
1 H), 3.78 (s, 3 H), 1.02 (s, 9 H), 0.17 (s, 6 H); 
13C NMR δ 152.2, 149.8, 135.8, 125.7, 108.2, 
99.2, 55.5, 26.1 (3 C), 19.0, -4.0 (2 C); HRMS calcd for C13H22ClO3Si (M+H
+
) 289.1027, found 
289.1000. 
 
Conversion of formate 21 to phenol 22  
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To a solution of 45 mg (0.142 mmol) of  21  in 2 mL of methanol, was added 98 mg (0.71 
mmol) of K2CO3 and stirred at 25
o
C for 4 hours. The reaction was diluted with 100 mL of 
diethyl ether and washed with 10 mL of aqueous NH4Cl, 10 mL of water, and 10 mL of brine. 
The organic layer was dried over anhydrous MgSO4, solvent evaporated, and the crude product 
was column chromatographed on silica gel using a mixture of hexane and diethyl ether (2:1) as 
eluent to give 37 mg of phenol 22 in 90% yield, which 
1
H NMR spectral data is identical to that 
described above.  
 
2-Bromo-4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (23) & 2-bromo-3-
chloro-5-methoxy-1,4-benzoquinone (19) 
 
 
 
To a solution of 84 mg (0.29 mmol) of  22 in 2 mL of DMF under argon, was added 57 
mg (0.32 mmol) of NBS and was stirred at 25
o
C for 12 h.  The reaction solution was diluted with 
100 mL of diethyl ether and washed with 10 mL of water followed by 10 mL of brine. The 
organic layer was dried over anhydrous MgSO4, concentrated, and column chromatographed on 
silica gel using a gradient mixture of hexane and diethyl ether as an eluent to give 27 mg of 23 
and 35 mg of 19 in 31% and 48% yield, respectively.  Bromophenol 23:  
1H NMR δ 6.56 (s, 1 
H), 5.33 (s, 1 H, OH), 3.78 (s, 3 H), 1.03 (s, 9 H), 0.18 (s, 6 H); 
13CNMR δ 151.5, 147.4, 136.8, 
125.8, 101.5, 98.4, 55.6, 26.1, 19.0, -3.9; HRMS calcd for C13H19BrClO3Si (M-H) 364.9975, 
found 365.0076; C13H20BrClO3SiNa (M+Na
+
) 388.9951, found 388.9934.  p-Benzoquinone 19 
(light yellow solid): Mp. 167 – 170oC; IR (neat) υ 2953, 2913, 2839, 1683, 1638, 1613, 1556, 
1454, 1229, 1168 cm
-1
; 
1H NMR δ 6.16 (s, 1 H), 3.89 (s, 3 H); 13C NMR δ 177.5, 172.4, 158.9, 
137.4, 107.9, 107.2, 57.3; HRMS calcd for C7H5BrClO3 (M+1
+
) 250.9105, found 251.0593. 
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Conversion of silyl ether 23 to p-benzoquinone 19 
 
 
 
To a solution of 25 mg (0.068 mmol) of silyl ether 23 in 2 mL of THF was added 68 µL 
(0.068 mmol) of n-Bu4NF (1 M in THF) and stirred under argon from 0
o
C for 30 minutes. The 
reaction was diluted with 50 mL of diethyl ether and washed with 10 mL of aqueous NH4Cl, 10 
mL of water, and 10 mL of brine. The organic layer was dried over anhydrous MgSO4, 
concentrated, and column chromatographed on silica gel using a mixture of hexane and diethyl 
ether (1:1) as an eluent to give 14 mg of p-benzoquinone 19 in 81% yield, which 
1
H NMR 
spectrum is identical to that described above.   
 
2-Bromo-3-chloro-5-methoxy-1,4-dihydroxybenzene (4) 
 
 
   
A mixture of 10 mg (0.040 mmol) of 19 and 2 mg of 10% palladium over carbon in 1 mL 
of ethanol under 1 atm. of hydrogen (a balloon filled with hydrogen connected to the round 
bottom flask) was stirred at 25
o
C for 15 minutes, filtered through Celite, and rinsed with 10 mL 
of ethanol.  The filtrate was concentrated to give 10 mg of 4 in quantitative yield: IR (neat) υ 
3303, (s), 2935, 2851, 1601, 1497, 1441, 1210, 1071, 1046, 994, 864, 842, 825 cm
-1
; 
1H NMR δ 
6.60 (s, 1 H), 5.50 (bs, 1 H, OH), 5.30 (bs, 1 H, OH), 3.89 (s, 3 H, OMe); 
13C NMR δ 148.2, 
147.7, 136.7, 121.1, 100.2, 99.4, 56.0; HRMS calcd for C7H6BrClO3 (M
+
) 251.9189, found 
252.0427. 
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3-Chloro-4,5-dihydroxybenzaldehyde (2)
26
 
 
 
 
To a solution of 10.14 g (5.43 mmol) of  2
26
 in 40 mL of dry CH2Cl2 at 0
o
C, was added 
0.57 mL (6 mmol) of boron tribromide (BBr3)  drop wise and the mixture was stirred under 
argon at 0
o
C for 30 minutes and then at 25
o
C for 12 hours.  The reaction was quenched with a 
slow addition of 50 mL of methanol followed by evaporation under rotavap.  The addition and 
evaporation of methanol were repeated 3 times (50 mL each time) to remove excess BBr3.  The 
crude product was then treated with 30 mL of 1:1 hexane and diethyl ether solution, filtered and 
washed with small amount of 1:1 hexane and diethyl ether solution to give 8.80 g (93.9%) of 2
26
 
as pure green solid. 
1
H NMR (Acetone-d6) δ  9.78 (s, 1H), 7.47 (d, J = 2.0 Hz), 7.34 (d, J = 2.0 
Hz); 
13
C NMR (Acetone-d6) δ 190.6, 148.8, 147.4, 130.8, 125.2, 121.5, 113.8. 
 
3,4-Bis(tert-butyldimethylsilyoxy)-5-chlorobenzaldehyde (24)
26 
 
 
 
To a solution of 0.80 g (4.64 mmol) of 2
26
 and 0.17 g (1.39 mmol) of 4-
dimethylaminopyridine (DMAP) in 10 mL of dry CH2Cl2 at 0
o
C under argon, were added 2.6 
mL (18.56 mmol) of triethylamine and 2.8 g (18.56 mmol) of tert-butyldimethylsilyl chloride 
and stirred at 0
o
C for 1 hour and then at 25
o
C for 3 hours.  The reaction mixture was diluted with 
100 mL of diethyl ether, washed with 20 mL of aq. NH4Cl followed by 20 mL of brine, dried 
over anhydrous MgSO4, and concentrated.  The crude product was column chromatographed on 
silica gel using a 10:1 mixture of hexane and diethyl ether as an eluent to give 1.46 g of desired 
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24
26
 in 79% yield.
 1H NMR δ 9.78 (s, 1 H), 7.50 (d, J = 2 Hz, 1 H), 7.29 (d, J = 2 Hz, 1 H), 1.05 
(s, 9 H), 0.99 (s, 9 H), 0.27 (s, 6 H), 0.24 (s, 6 H); 
13C NMR δ 190.1, 149.9, 149.4, 130.3, 128.0, 
126.0, 119.0, 26.3 (3 C), 26.2 (3 C), 19.0, -3.2, -3.4; HRMS calcd for C19H34ClO3Si2 (M+H
+
) 
401.1735, found 401.1747. 
 
3,4-Bis(tert-butyldimethylsilyloxy)-5-chlorophenyl formate (25)
26
 
 
 
 
To a solution of 1.01g (5.43 mmol) of 24 in 20 mL of dry CH2Cl2 was added 1.6 g (6.45 
mmol) of m-chloroperoxybenzoic acid (70% pure) and refluxed at 50
o
C for 10 hours. The 
reaction mixture was diluted with 500 mL of diethyl ether, washed with 100 mL of aq. NaHCO3, 
100 mL of water and 100 mL of brine.  The organic layer was dried over anhydrous MgSO4, 
concentrated, and column chromatographed on silica gel using a mixture of diethyl ether and 
hexane (10:1) as an eluent to give 1.42 g of 25
26 
 in 79% yield . 
1
H NMR δ 8.22 (s, 1 H, OCHO), 
6.79 (d, J = 3.2 Hz, 1 H), 6.58 (d, J = 3.2 Hz, 1 H), 1.03 (s, 9 H, t-Bu), 0.96 (s, 9 H, t-Bu), 0.22 
(s, 6 H, Me), 0.19 (s, 6 H, Me); 
13
C NMR δ 159.0 (CHO), 148.8, 143.0, 142.4, 127.1, 115.5, 
113.1, 26.2 (6 C, t-Bu), 18.8 (2 C, t-Bu), -3.3 (2 C, Me), -3.6 (2 C, Me). 
 
3,4-Bis(tert-butyldimethylsilyloxy)-5-chlorophenol (26)
26 
 
 
 
To a solution of 1.24 g (3 mmol) of 25 in 30 mL of methanol, was added 2.21 g (15 
mmol) of K2CO3 and stirred at room temperature for 12 h.  The reaction was diluted with 70 mL 
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ethyl acetate and washed with 20 mL of aq. NH4Cl followed by 20 mL of brine.  The organic 
layer was dried over anhydrous MgSO4 and concentrated to give 0.6 g of 26
26
 which was used in 
the next step without further purification.  
1
H NMR δ 6.47 (d, J = 2.9 Hz, 1 H), 6.30 (d, J = 2.9 
Hz, 1 H), 1.02 (s, 9 H, t-Bu), 0.97 (s, 9 H, t-Bu), 0.22 (s, 6 H, Me), 0.17 (s, 6 H, Me); 
13
C NMR δ 
149.7, 148.9, 137.7, 126.9, 109.8, 107.8, 26.3 (3 C), 26.2 (3 C), -3.6 (2C, Me), -3.4 (2 C, Me). 
 
2-Bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-chlorophenol (27)
26 
 
 
 
To a solution of 0.42 g (1.08 mmol) of  26 in 8 mL of dry DMF under argon at 25
o
C, was 
added 0.19 g (1.08 mmol) of N-bromosuccinimide and stirred at 25 
o
C for 22 hours.  The 
reaction was diluted with 50 mL of ethyl acetate and washed twice with 15 mL of water followed 
by 15 mL of brine.  The organic layer was dried over anhydrous MgSO4, concentrated, and 
column chromatographed using a gradient mixture of hexane and diethyl ether as an eluent to 
give 0.18 g of  27
26 
 in 63% yield; based on the recovery of 0.18 g of starting material 26. 
1
H 
NMR δ 6.65 (s, Ar, 1 H), 5.27 (s, OH), 1.03 (s, t-Bu,  9 H), 0.97 (s, t-Bu,  9 H), 0.23 (s, CH3, 6 
H), 0.17 (s, CH3, 6 H); 
13C NMR δ 148.3, 147.4, 138.8, 127.0, 106.9, 102.9, 26.2 (t-Bu), 18.8, -
3.3 (Me), -3.5 (Me). 
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2-Bromo-4,5-bis-(tert-butyldimethylsilyloxy)-3-chloro-1-methoxybenzene (28) 
 
 
 
   To a solution of 0.10 g (0.21 mmol) of  27
 
in 2 mL of dichloromethane at 0
o
C and  under 
argon, were added 55 mg (0.26 mmol) of proton sponge and 38 mg (0.26 mmol) of 
trimethyloxonium tetrafluoroborate, and the mixture was stirred at 0
o
C for 8 h.  The reaction was 
diluted with 15 mL of water and extracted twice with 50 mL of diethyl ether.  The organic layer 
was washed with 10 mL of water followed by 10 mL of brine, dried over anhydrous MgSO4, 
concentrated, and column chromatographed on silica gel using a mixture of hexane and diethyl 
ether (10:1) as eluent to give 67 mg of 28 in 95% yield; based on the recovery of 31 mg of 
compound 27.  
1H NMR δ 6.43 (s, 1 H), 3.80 (s, 3 H), 1.03 (s, 9 H), 0.98 (s, 9 H), 0.23 (s, 6 H), 
0.17 (s, 6 H); 
13C NMR δ 151.0, 147.5, 138.9, 128.9, 104.7, 104.5, 56.9, 26.3 (6 C), 18.9, 18.8, -
3.3 (2 C), -3.5 (2 C); HRMS calcd for C19H35BrClO3Si2 (M+H
+
) 481.0996, found 481.0951. 
 
4-Bromo-3-chloro-5-methoxybenzene-1,2-diol (3) 
 
 
 
  To a solution of 51 mg (0.10 mmol) of 28 in 2 mL of THF at 0
o
C under argon, was added 
0.20 mL (0.20 mmol) of n-Bu4NF, and the solution was stirred for 30 min.  The reaction was 
diluted with 100 mL of diethyl ether, washed with 10 mL of water followed by 10 mL of brine, 
dried over anhydrous MgSO4, concentrated, and column chromatographed on silica gel using a 
gradient mixture of dichloromethane and methanol as an eluent to give 19 mg of 3 in 71% yield.  
IR (neat) υ 3436, 3219 (broad & s), 2917, 2851, 1580, 1462, 1417, 1315, 1188, 1070, 984, 820 
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cm
-1
; 
1
H NMR δ 6.59 (s, 1 H), 5.60 (bs, 1 H, OH), 5.24 (bs, 1 H, OH), 3.83 (s, 3 H); 13C NMR δ 
151.4, 144.4, 134.2, 121.8, 101.7, 99.7, 57.1; HRMS calcd. for C7H7BrClO3 C7H7BrClO3 
(M+H
+
) 252.9267, found 252.9254.  
 
3-(tert-Butyldimethylsilyloxy)-5-chloro-4-hydroxybenzaldehyde (29) 
 
 
 
   To a solution of 3.2 g (19 mmol) of 2 in 60 mL of CH2Cl2 at 0
o
C under argon, were 
added 2.9 mL (22 mmol) of triethylamine, 0.45 g (3.7 mmol) of 4-dimethylaminopyridine, and 
3.4 g (22 mmol) of tert-butyldimethylsilyl chloride and the solution was stirred at 25
o
C for 8 h.  
The reaction was diluted with 500 mL of diethyl ether and washed with 50 mL water and 50 mL 
of brine. The organic layer was dried over anhydrous MgSO4, concentrated, and column 
chromatographed on silica gel using hexane and dichloromethane (1:1) as an eluent to give 3.7 g 
of 29 and 0.84 g of 24 in 70% and 11% yield, respectively.  Compound 29 was crystallized from 
diethyl ether to provide single crystals and its structure was unequivocally identified by a single-
crystal X-ray analysis (Figure 1.5).  Compound 29: 
1H NMR δ 9.76 (s, 1H, CHO), 7.51 (d, J = 
2.8 Hz, 1 H), 7.27 (d, J  = 2.8 Hz, 1 H), 6.24 (s, 1 H, OH), 1.03 (s, 9 H), 0.32 (s, 6 H); 
13
C NMR 
δ 189.9, 149.9, 144.2, 129.4, 126.8, 120.7, 115.9, 25.8, 18.4, -4.2; HRMS calcd for C13H20ClO3Si  
(M+H
+
) 287.0870, found 287.0858.  Compound 24: 
1H NMR δ 9.78 (s, 1 H), 7.50 (d, J = 2 Hz, 
1 H), 7.29 (d, J = 2 Hz, 1 H), 1.05 (s, 9 H), 0.99 (s, 9 H), 0.27 (s, 6 H), 0.24 (s, 6 H); 
13C NMR δ 
190.1, 149.9, 149.4, 130.3, 128.0, 126.0, 119.0, 26.3 (3 C), 26.2 (3 C), 19.0, -3.2, -3.4; HRMS 
calcd for C19H34ClO3Si2 (M+H
+
) 401.1735, found 401.1747. 
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3-(tert-Butyldimethylsilyloxy)-5-chloro-4-methoxybenzaldehyde (30) 
 
 
 
To a solution of 0.45 g (1.57 mmol) of 29 in 10 mL of dichloromethane at 0
o
C under 
argon, were added 0.67 g (3.14 mmol) of proton sponge and 0.47 g (3.14 mmol) of 
trimethyloxonium tetrafluoroborate, and stirred at 0
o
C for 12 hours.  The reaction mixture was 
diluted with 200 mL of diethyl ether and washed with 30 mL of aqueous NH4Cl solution, 30 mL 
of water, and 30 mL of brine.  The organic layer was dried over anhydrous MgSO4, concentrated, 
and column chromatographed on silica gel using a mixture of hexane and diethyl ether (10:1) as 
an eluent to give 0.20 g of  30 in 78% yield; based on the recovery of  0.21 g of 29 : 
1H NMR δ 
9.83 (s, 1H, CHO), 7.54 (d, J = 1.8 Hz, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 3.91 (s, 3 H), 1.03 (s, 9 
H), 0.23 (s, 6 H); 
13C NMR δ 190.1, 153.4, 150.9, 132.8, 129.8, 125.5, 119.9, 60.7, 25.8, 18.4, -
4.4; HRMS calcd for C14H22ClO3Si (M+H
+
) 301.1027, found 301.1421; negative ion detection 
mode: C14H20ClO3Si (M-H) 299.0870, found 298.9978. 
 
 
3-(tert-Butyldimethylsilyloxy)-5-chloro-4-methoxyphenyl formate (31) & 3-(tert-
butyldimethylsilyloxy)-5-chloro-4-methoxyphenol (32) 
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To a solution of 0.13 g (0.432 mmol) of 30 in 2 mL of dichloromethane at 0 
o
C and under 
argon, was added 0.16 g (70% pure; 0.648 mmol) of  m-chloroperbenzoic acid, and the solution 
was refluxed for 12 hours.  The reaction solution was diluted with 5 mL of aqueous sodium 
thiosulfate and 200 mL of diethyl ether. The solution was washed with 20 mL water followed by 
20 mL of brine.  The organic layer was dried over anhydrous MgSO4, concentrated, and  column 
chromatographed on silica gel using a mixture of hexane and diethyl ether (10:1) as an eluent to 
give 58 mg of 31 and 55 mg of hydrolyzed product 32 in 42% and 44% yield, respectively. 
Compound 31:
1H NMR δ 8.23 (s, 1 H, OCHO), 6.83 (d, J = 2.6 Hz, 1 H), 6.59 (d, J = 2.6 Hz, 1 
H), 3.81 (s, 3 H), 1.01 (s, 9 H), 0.21 (s, 6 H); 
13C NMR δ 158.9, 150.7, 146.6, 145.4, 129.1, 
115.8, 113.6, 60.7, 25.8 (3 C), 18.4, -4.5; HRMS calcd for C14H22ClO4Si (M+H
+
) 317.0976, 
found 317.1355. Compound 32:
 1H NMR δ 6.48 (d, J = 2.6 Hz, 1 H), 6.29 (d, J = 2.6 Hz, 1 H), 
3.75 (s, 3 H), 1.01 (s, 9 H), 0.20 (s, 6 H); 
13C NMR δ 152.0, 150.7, 142.6, 128.1, 110.8, 108.6, 
60.7, 25.8 (3 C), 18.4, -4.5; HRMS calcd for C13H22ClO3Si (M+H
+
) 289.1027, found 289.1041. 
 
Conversion of formate 31 to phenol 32 
 
 
 
A solution of 55 mg (0.18 mmol) of compound 31 and 0.13 g (0.91 mmol) of K2CO3 in 1 
mL of methanol was stirred at 25
o
C for 12 h. The reaction was diluted with 10 mL of water and 
30 mL of ethyl acetate and the solution washed with 5 mL of aqueous NH4Cl solution, 5 mL of 
water, and 5 mL of brine. The organic layer was dried over anhydrous MgSO4, concentrated, and 
column chromatographed on silica gel using a mixture of hexane and diethyl ether (10: 1) as an 
eluent to give 50 mg of compound 32 in quantitative yield, which 
1
H NMR spectrum is identical 
to that described above. 
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2-Bromo-5-(tert-butyldimethylsilyloxy)-3-chloro-4-methoxyphenol (33) 
 
 
    
To a solution of 75 mg (0.26 mmol) of 32 in 2 mL of dimethylformamide (DMF) under 
argon, was added 51 mg (0.28 mmol) of N-bromosuccinimide and the solution was stirred at 
25
o
C for 12 h.  The reaction mixture was diluted with 100 mL of diethyl ether, washed with 10 
mL of water followed by 10 mL of brine, and the organic layer was dried over anhydrous 
MgSO4.  The solvent was evaporated and the crude product was column chromatographed on 
silica gel using a mixture of hexane and diethyl ether (10:1) as an eluent to give 64 mg of 33 in 
67% yield:  Mp. 44 – 45oC; 1H NMR δ 6.55 (s, 1 H), 5.42 (s, 1 H, OH), 3.77 (s, 3 H), 1.01 (s, 9 
H), 0.20 (s, 6 H); 
13C NMR δ 150.2, 149.6, 143.1, 124.2, 107.2, 103.0, 60.8, 25.8 (3 C), 18.5, -
4.5; HRMS calcd for C13H21BrClO3Si (M+H
+
) 367.0132, found 367.0142. 
 
4-Bromo-5-chloro-6-methoxybenzene-1,3-diol (5) 
 
 
 
  To a solution of 40 mg (0.108 mmol) of 33 in 2 mL of dry THF under argon at 0
o
C, was 
added 120 µL (0.12 mmol) of n-Bu4NF (1 M solution in THF) and the solution was stirred at 0
o
C 
for 30 min.  The reaction was diluted with 70 mL of diethyl ether, washed with 10 mL of water 
followed by 10 mL of brine, and the organic layer was dried over anhydrous MgSO4.  The 
solvent was concentrated and the crude product was column chromatographed on silica gel using 
a mixture of ethyl acetate and hexane (2:1) as an eluent to give 15 mg of 5 in 60% yield.  IR 
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(neat) υ 3321 (bs), 3260, 2917, 1589, 1421, 1241, 984, 800; 1H NMR δ 6.65 (s, 1 H), 3.87 (s, 3 
H); 
13C NMR δ 150.5, 150.0, 138.7, 127.5, 101.8, 101.7, 61.5; HRMS calcd for C7H7BrClO3 
(M+H
+
) 252.9267, found 252.9279. 
 
2-Bromo-3-chloro-4,5-dibenzyloxyphenol (35) 
 
 
    
To a solution of 0.10 g (0.188 mmol) of 34
26
 in 3 mL of tetrahydrofuran (THF) at 0
o
C, 
was added 210 µL of n-Bu4NF (1 M in THF) and stirred under argon at 0
o
C for 30 minutes.  The 
solution was diluted with 100 mL of diethyl ether, washed with 10 mL of water followed by 10 
mL of brine, and the organic layer was dried over anhydrous MgSO4.  The dry organic layer was 
concentrated and the crude product was column chromatographed on silica gel using a mixture of 
hexane and diethyl ether (10:1) as an eluent to give 56 mg of 35 as white solids in 74% yield. 
Mp.= 108 – 110 oC; 1H NMR δ  7.40 - 7.20 (m, 10 H), 6.66 (s, 1 H), 5.07 (s, 2 H), 4.96 (s, 2 H);  
13C NMR δ 153.1, 149.9, 139.8, 137.0, 136.1, 129.2, 128.8, 128.5, 128.44, 128.40, 127.6, 102, 
100.6, 75.4, 71.3; HRMS calcd for C20H17BrClO3 (M+H
+
) 419.0044, found 419.0051. 
 
5-Bromo-6-chlorobenzene-1,2,4-triol (6) 
 
 
To a solution of 25 mg (0.06 mmol) of  35 in 1 mL of ethanol, was added 2.5 mg of 10% 
palladium/carbon and was stirred under 1 atmosphere of hydrogen (a balloon filled with 
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hydrogen was connected to the round bottom flask) at 25
o
C for 3 h.  The reaction mixture was 
filtered through Celite and concentrated to dryness to give 13 mg of 6 in 93% yield.  The triol 6 
was stored in a dry box under nitrogen atmosphere:  Mp. >350 
o
C; IR (neat) υ 3382 (bs, OH 
stretch), 2932, 2843, 1614, 1437, 1285, 1170, 1070 cm
-1
; UV (in methanol)  209.6 (εmax = 
30300), 291.8 (1250; likely derived from a partial oxidation of the polyphenol functions), 332.5 
(4640), 397.1 (1785) nm;  
1
H NMR (CD3OD) δ 6.66 (s, 1 H, Ar), 5.58 (bs, 1 H, OH), 5.27 (bs, 1 
H, OH), 5.21 (bs, 1 H, OH); 
13
C NMR (CD3OD) δ 149.4, 147.6, 137.4, 123.1, 103.2, 100.6; 
HRMS calcd for C6H5BrClO3 (M+H
+
) 238.9105, found 238.9111.  
 
2-Amino-4-(hydroxymethyl)phenol (7)
23
 &  2-amino-4-methylphenol (8)
24 
 
 
 
   To a solution of 0.30 g (1.8 mmol) of 36 in 30 mL of ethanol was added 0.15 g of 10% 
palladium over carbon and shaken on a hydrogenator under 30 psi atmosphere of hydrogen for 4 
h.  The reaction mixture was filtered through Celite, and the Celite was carefully rinsed with 30 
mL ethyl acetate. The filtrate was concentrated and the crude was column chromatographed on 
silica gel using a mixture of dichloromethane and methanol (9:1) as eluent to give 0.1 g of 7
23
 
and  91 mg of 8
24
, both in 41% yield. Compound 7: IR (neat) υ 3387 (sharp, m), 3313 (sharp, 
m), 3047 (broad), 2802, 1605, 1515, 1454, 1364, 1286, 1221, 1155, 1008, 816 cm
-1
;  
1
H NMR 
(D2O) δ 6.88 (d, J = 1.2 Hz, 1 H), 6.85 (d, J = 8 Hz, 1 H), 6.77 (dd, J = 8, 1.2 Hz, 1 H), 4.49 (s, 2 
H); 
13
C NMR (DMSO-d6) δ 144.9, 136.1, 133.4, 114.9, 113.8, 113.4, 63.3.Compound 8: IR 
(neat) υ 3370 (sharp, m), 3301 (sharp, m), 2921, 1601, 1519, 1458, 1388, 1286, 878, 800 cm-1; 
1H NMR δ 6.62 (d, J = 7.6 Hz, 1 H), 6.58 (d, J = 1.6 Hz, 1 H), 6.48 (dd, J = 7.6, 1.6 Hz, 1 H), 
2.21 (s, 3 H); 
13C NMR δ 141.9, 134.4, 131.2, 120.0, 118.1, 115.4, 20.9.   
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1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (10)
30 
 
 
 
To 1 g (7.5 mmol) of anhydrous AlCl3 under argon was added 1mL (9.5 mmol) of 
isobutyryl chloride (38) at -10
o
C followed by 1.2 g (5.8 mmol) of 2,6-di-tert-butylphenol (37). 
To the reaction mixture, 1 mL (9.5 mmol) of isobutyryl chloride was again added and shaken 
vigorously for 15 minutes till light pink paste was formed. The reaction was quenched with 50 
mL of ice cold water and extracted thrice with 50 mL of ethyl ether. The combined organic 
layers were washed with 20 mL brine, dried over anhydrous MgSO4 and concentrated to give 
1.4208 g of (10)
30
 in 90% yield. Thin layer chromatography (TLC) and NMR analysis indicated 
that the compound was pure and was used in the next step without further purification.
1H NMR δ 
7.89 (S, Ar, 2 H), 5.71 (s, OH, 1 H), 3.55 (m, 1 H), 1.48 (s, t-Bu, 18 H), 1.25 (d, J = 6.6 Hz, CH3, 
6 H); 
13C NMR δ 204.1, 158.4, 135.9, 127.9, 126.2, 34.91, 34.6, 30.3, 19.7. 
 
2-Bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (11)
31
 
 
 
 
To a solution of 0.19 g (0.69 mmol) of 10 in a mixture of 0.5 mL of dry CH2Cl2 and 1 mL 
of dry ethyl acetate under argon, was added 0.37 g (1.68 mmol) of cupric bromide and heated to 
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reflux for 3 hours at 70
o
C.  The reaction was filtered and concentrated to give 0.23 g of (11)
31
 as 
yellow colored solid in 96% yield. Thin layer chromatography (TLC) and NMR analysis 
indicated that the compound was pure and was used in the next step without further purification. 
1H NMR δ 8.17 (s, Ar, 2 H), 5.75 (s, OH, 1 H), 2.06 (s, CH3, 6 H), 1.48 (s, t-Bu, 18 H); 
13
C 
NMR δ 195.7 (C=O), 158.2, 135.6, 128.8, 125.6, 60.6, 34.7, 32.4, 30.4. 
 
2,6-Di-tert-butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol (12)
31 
 
 
 
To a solution of 0.23 g (0.65 mmol) of 11 in 3 mL of dry ethyl ether at 0
o
C under argon, 
was added 55 mg (1.46 mmol) of LiAlH4 on vigorous stirring and refluxed at 55
o
C for 3 hours. 
The reaction was carefully quenched by the addition of 20 mL of water followed by the addition 
of 2 mL of 1M H2SO4. The reaction was then extracted with 100 mL of diethyl ether. The 
organic layer was washed with 20 mL of brine, dried over anhydrous MgSO4, and solvent 
evaporated to give 180 mg of 12
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 as white solid in quantitative yield. Thin layer 
chromatography (TLC) and NMR analysis indicated that the compound was pure and was used 
in the next step without further purification. 
1H NMR δ 7.19 (s, Ar, 2 H), 5.13 (s, Ar-OH, 1 H), 
3.57 (d, J = 6.6 Hz, 2 H), 1.45 (s, t-Bu, 18 H), 1.33 (s, CH3, 6H); 
13C NMR δ 152.2, 136.4, 135.6, 
123.0, 73.6, 40.1, 34.8, 30.5, 25.7.  
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2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal (13) 
 
 
 
To a solution of 0.17 g (0.61 mmol) of 12 in 3 mL of dimethyl sulfoxide (DMSO), was 
added 0.21 g (0.73 mmol) of o-iodoxybenzoic acid (IBX) and stirred under argon at 25 
o
C for 12 
h. The reaction was diluted with 200 mL of CH2Cl2, washed with 30 mL of water followed by 30 
mL of brine, dried over anhydrous MgSO4, and concentrated to give 0.17 g of 13 in quantitative 
yield.  Thin layer chromatography (TLC) and NMR analysis indicated that the compound was 
pure and was used in the next step without further purification.  IR (neat) υ 3603 (OH), 2952, 
2900, 2700 (C-H aldehyde), 1714 (C=O aldehyde), 1435, 1360, 1230, 1141, 1120, 903, 826, 
744;  
1
H NMR δ 9.45 (s, 1 H, CHO), 7.06 (s, 2 H, Ar), 5.22 (s, 1 H, OH), 1.44 (s, 24 H, Me); 13C 
NMR δ 202.8 (C=O), 153.1, 136.2 (2 C), 131.4, 123.6 (2 C), 50.4, 34.8, 30.4 (t-Bu), 22.7; MS 
negative mode: m/z 275.6 (M-1); positive mode: m/z 299.4 (M+Na
+
). 
 
2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime (15) 
 
 
    
To a solution of 40 mg (0.14 mmol) of 13 in 3 mL of acetonitrile and water (2:1), were 
added 25 mg (0.35 mmol) of  NH2OH•HCl and 60 mg (0.43 mmol) of sodium acetate, and the 
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solution was stirred at 25
o
C for 1.5 h.  The reaction mixture was concentrated, diluted with 20 
mL of water, and extracted three times with diethyl ether (60 mL total).  The combined extract 
was concentrated to give 41 mg of 15 in 97% yield.  Thin layer chromatography (TLC) and 
NMR analysis indicated that the compound was pure.  
1H NMR δ 7.49 (s, 1 H, CH=N), 7.12 (s, 2 
H, Ar), 1.47 (s, 6 H, Me), 1.44 (s, 18 H, t-Bu); 
13C NMR δ 158.7 (C=N), 152.5, 135.9, 135.7, 
122.9 (2 C), 41.0, 34.7, 30.5 (6 C), 26.9; MS m/z 314 (M+Na
+
). 
 
4-[(2-Benzylamino)-1,1-dimethylethyl]-2,6-di-tert-butylphenol (16) 
 
 
    
To a solution of 50 mg (0.18 mmol) of 15 in 3 mL of toluene was added 19 µL (0.18 
mmol) of benzylamine and heated to reflux using a Diel’s Stark apparatus for 12 h.  Toluene was 
evaporated under rotovapor, the crude was dissolved in 2 mL of methanol, and 18 mg (0.29 
mmol) of NaCNBH3 was added. The resulting solution was stirred for 2 h, diluted with 20 mL of 
water, and extracted twice with ethyl acetate (100 mL total).  The combined extract was washed 
with 10 mL of water and 10 mL of brine, dried over anhydrous MgSO4, and concentrated to give 
68 mg of 16 in 98% yield.  Thin layer chromatography (TLC) and NMR analysis indicated that 
the compound was pure.  
1H NMR δ 7.35 – 7.18 (m, 5 H, Ph), 7.13 (s, 2 H, Ar), 5.08 (broad s, 1 
H), 3.72 (s, 2 H, CH2N), 2.68 (s, 2 H, CH2N), 1.43 (s, 18 H, t-Bu), 1.33 (s, 6 H, Me); 
13C NMR δ 
151.92, 140.4, 137.8, 135.4, 128.5, 128.1, 127.0, 122.7, 61.5, 54.2, 38.6, 34.7, 30.6, 27.9; MS 
m/z 368.5 (M+1). 
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2,4-Di-tert-butyl-6-(3-methyl-2-butenyl)phenol (17) and 6,8-di-tert-butyl-2,2-dimethyl-3,4-
dihydro-2H-chromene (18) 
 
 
 
  To a solution of 0.20 g (1.44 mmol) of 40 in 3 mL of dichloromethane at -78
o
C under 
argon, were added 0.18 mL (1.44 mmol) of BF3•ether followed by 0.21 g (0.96 mmol) of 39.  
The solution was warmed to 25 
o
C and stirred for 1 h.  The reaction mixture was diluted with 200 
mL of diethyl ether, washed with 20 mL of aqueous NaHCO3 followed by 20 mL of brine, the 
organic layer was dried over anhydrous Na2SO4, concentrated, and column chromatographed on 
silica gel using 1% diethyl ether in hexane as eluent to give 0.12 g of 17 and 26 mg of 18 in 46% 
and 10% yield, respectively.  Compound 17:  
1H NMR δ 7.22 (d, J = 3 Hz, 1 H, Ar), 6.99 (d, J = 
3 Hz, 1 H, Ar), 5.34 (t,hept, J = 7, 1 Hz, 1 H, =CH), 3.37 (d, J = 7 Hz, 2 H, CH2), 1.85 (s, 3 H, 
Me), 1.80 (s, 3 H, Me), 1.43 (s, 9 H, t-Bu), 1.31 (s, 9 H, t-Bu); 
13C NMR δ 151.5, 142.3, 135.9, 
135.7, 126.0, 125.0, 122.6, 122.3, 35.1, 34.4, 31.9 (3 C), 31.7, 30.0 (3C), 26.0, 18.2; MS 
negative mode: m/z 273.8 (M-1). Compound 18:  
1H NMR δ 7.14 (d, J = 3 Hz, 1 H, Ar), 6.93 
(d, J = 3 Hz, 1 H, Ar), 2.79 (t, J = 7 Hz, 2 H, CH2), 1.79 (t, J = 7 Hz, 2 H, CH2), 1.39 (s, 9 H, t-
Bu), 1.36 (s, 6 H, Me), 1.30 (s, 9 H, t-Bu); 
13C NMR δ 150.3, 141.0, 136.9, 124.2, 121.8, 119.9, 
73.9, 35.2, 34.3, 33.0, 31.9, 30.0, 27.3, 23.5; MS positive mode: m/z 275.2 (M+1). 
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Chapter 2. Distribution of CP2 and TP70 in  
mouse brain region and various tissues of mice. 
 
2.1  Introduction 
 
Alzheimer’s disease (AD), the most common type of dementia, was first described in 
1906 by Alois Alzheimer, a German neurologist.  “Dementia” is an umbrella term describing a 
variety of diseases and conditions that develop when nerve cells in the brain (called neurons) die 
or no longer function normally.  The death or malfunction of neurons causes changes in one’s 
memory, behavior, motor functions and ability to think clearly.  In AD, these changes in the 
brain eventually impair an individual’s ability to carry out such basic bodily functions as walking 
and swallowing.  AD is ultimately fatal.1,2 
 
More than 35 million people worldwide and 5.5 million in the United States suffer AD.  
With the general increase in longevity of the U.S. population, the incidence of AD has risen to 
the point where it is now the sixth-leading cause of death in the US and the fifth-leading cause of 
death for individuals age 65 and older.  By 2025, the number of people 65 and older with AD is 
estimated to reach 7.1 million.
3
  No treatment is available to slow or stop the disease. Four 
medications approved by the U.S. Food and Drug Administration that temporarily improve 
symptoms are Donepezil (Aricept
®
), rivastigmine (Exelon
®
), galantamine (Razadyne
®
) and 
memantine (Namenda
®
).  However, these drugs do not ameliorate the underlying disease process 
and may help only for a few months to a few years.  The development of new anti-AD drugs are 
highly warranted.
4
 
 
Previous study in our laboratory has found that a tricyclic pyrone (TP) compound, CP2 
(code name; Figure 2.1) showed the prevention of cell death from MC65 cells assay associated 
with intracellular amyloid beta oligomers (AβO) and inhibits Aβ aggregation in vitro and 
reduced amyloid plaques and soluble AβO in vivo.5,6  Recently, further exploration of similar 
analogs by modifying C13 position in CP2, TP70 (code name; Figure 2.1) was identified to 
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possess strong cell protective properties against intracellularly induced Aβ toxicity, inhibitory 
activities against Acyl-CoA: cholesterol acyltransferase (ACAT), and enhancing properties of 
ATP-binding cassette subfamily A member 1 (ABCA1) cholesterol transporter gene with 
nanomolar efficacy.
7
   
 
 
 
Figure ‎2.1  Chemical structure of CP2 and TP70. 
 
My research project involved the synthesis of CP2 and TP70 in gram scale reactions for 
in vivo studies and studies of the pharmacokinetics (PK) and bioavailability.  After that, 
quantifications of CP2 and TP70 in mouse brain regions and various tissues of mice were 
determined using high-performance liquid chromatography (HPLC).  These studies are essential 
to define the pharmacokinetics and metabolisms of these drugs in mice which can be used to 
design the optimal dose of compounds for in vivo efficacy study. 
 
 Oral feeding or intravenous (iv) administration of CP2 and neuronal cultures and mouse 
brain region collection were conducted by Dr. Eugenia Trushina and Dr. Liang Zhang at Mayo 
Clinic.  Oral or intravenous (iv) route of TP70 and tissues collection were done by Dr. Ximin 
Simon Xie group, AfaSci Research Laboratory.  In this chapter, the distribution of CP2 in 
neuronal cultures and mouse brain region and the time course distribution of TP70 in different 
tissues and plasma of mice are presented and discussed.  
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2.2  Background 
 
AD can be classified in two forms: (1) the rare, early onset familial form of AD  (FAD) is 
caused by mutations in the amyloid precursor protein (APP) and presenilin 1 and 2 (PS1 and 
PS2) genes that lead to the accumulation of Aβ; and (2) a common sporadic non-familial AD, 
which results in the generation of Aβ42.  APP is a transmembrane glycoprotein and is found in 
many tissues and organs, including the brain and spinal cord (central nervous system). Its 
primary function is not known, though it has been implicated as a regulator of synapse 
formation, neural plasticity and iron export.  Presenilins are a family of related multi-pass 
transmembrane proteins that function as a part of the gamma-secretase intramembrane 
protease complex. Vertebrates have two presenilin genes, called PSEN1 (located on chromosome 
14 in humans) that encodes presenilin 1 (PS1) and PSEN2 (on chromosome 1 in humans) that 
codes for presenilin 2 (PS-2).  Notably, patients with either sporadic or familial AD share 
common clinical and neuropathological markers including Aβ plaques, accumulation of 
neurofibrillar tangles and massive neuronal cell loss. 
9-13
 
 
The mechanism of AD is yet to be known, however, it is believed that AD develops as a 
result of multiple factors rather than a single cause.  Extracellular β-amyloid (Aβ) peptide 
plaques and intracellular neurofibrillary tangles (NFTs) are two main pathological features of 
AD which distinguishes AD from other neurodegenerative diseases.
8-9 
 Aβ peptide are natural 
products of metabolism consisting of 36 to 43 amino acid.  Aβ peptide originates from 
proteolysis of the APP by sequential enzymatic actions of two enzymes, β-secretase and γ-
secretase.   Neurofibrillary tangles are mainly composed of intracellular hyperphosphorylated 
taus in the form of paired helical filaments.  Tau is a microtubule stabilizing protein.  When tau 
is hyperphosphorylated, it dissociates from microtubes causing their disassembly or loss of 
essential functions.
10
 In addition, hyperphosphorylated tau tends to aggregate and sequester 
additional normal tau from binding microtubes.  According to the amyloid cascade hypothesis, 
Aβ is the main culprit triggering a whole cascade of events, including formation of NFTs, 
eventually leading to neurodegeneration and loss of brain function in AD patients.
4,11 
  Other risk 
factors associated with the development of AD are age, food, cholesterol, head injury,
 
 and 
family’s genetic, and behavioral history.12-14  
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Recent studies suggested that the intraneuronal accumulation of Aβ are the primary toxic 
species and might be the first step of amyloid cascade leading to the AD.
14-15
   Also it has been 
suggested that intracellular Aβ induces a higher toxicity, being at least 10,000 times more toxic 
than extracellular Aβ.16-17  Therefore,  drugs targeting Aβ and downstream events could be one 
of the primary therapeutic targets in AD.  Previous studies
5-6
 in our lab demonstrated that 
tricyclic pyrone CP2 ameliorates cell death associated with binding to Aβ42 oligomers, reducing 
the levels of intracellular Aβ,  and disaggregating Aβ42 oligomers and protofibrils.  Furthermore, 
it was found that long-term CP2 treatment not only restores memory but also improves motor 
function in AD mouse models. (These experiments were performed by Dr. Eugenia Trushina’s 
group at Mayo Clinic, the data are not shown here and the results are being formulated into a 
manuscript to be submitted). 
 
New findings from epidemiological, molecular and biochemical strongly support the 
involvement of cholesterol metabolism in the control of both the generation and/or accumulation 
of Aβ.18  For example, the identification of ε4 gene, an AD biomarker, of apolipoprotein E 
(APOE) as the most common genetic risk factor for late-onset AD.
19-20
  Moreover, the neurons 
with tangles were found to have higher level of cholesterol compared to the healthy neurons.
21-22 
 
ATP-binding cassette subfamily A member 1 (ABCA1), cholesterol transporters through cell 
membrane, is also shown to mediate the secretion of Aβ from the cells.23  Acetyl-coenzyme A 
acetyltransferases (ACAT)  is essential for the regulation of intracellular cholesterol homeostasis 
and distribution of cholesterol throughout the body by converting free cholesterol to neutral 
cholesteryl ester for storage.  The inhibition of ACAT will reduce the formation of cholesterol 
ester and increasing the level of free cholesterol inside the cells, which then induce cholesterol 
efflux by increasing the cholesterol transporter gene ABCA1.
24
  Therefore,  ACAT inhibitors are 
good candidates for regulating of amyloid pathology by regulating cholesterol homeostasis.
25-27
  
The lead compounds CP2 and TP70 possess inhibitory activity against ACAT along with the 
upregulation of ABCA1 gene promoting the efflux of cholesterol, increasing the efficiency of 
cholesterol transporters, restoring axonal trafficking, and enhancing hippocampal synaptic 
activity.  Like CP2, TP70 also protects the neuronal cell death.  In addition, both CP2 and TP70 
were found to have high oral bioavailability, excellent blood brain barrier permeability and low 
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toxicity.  These synergistic cellular actions could be potential mechanisms underlying the 
protective effects in vivo.  
 
Increasing evidence suggests that mitochondria are involved in aging which is the major 
risk factor for AD.  Even though the primary cause for mitochondrial dysfunction with age is still 
controversial, studies in several species reveal a wide spectrum of alterations in mitochondria 
and mitochondrial DNA (mtDNA) with aging, including (1) increased disorganization of 
mitochondrial structure, (2) decline in mitochondrial oxidative phosphorylation function, (3) 
accumulation of mtDNA mutation, (4) increased mitochondrial production of reactive oxygen 
species (ROS), and (5) increased extent of oxidative damage to DNA, proteins, and lipids.  
Mitochondria are the most complex and metabolically active organelles in the cell. 
28-30 
 
Recent studies
31-35
 also have linked the Aβ with mitochondrial dysfunction.  The 
mechanism of mitochondria dysfunction in AD is controversial.  These studies suggests that Aβ 
enters mitochondria and interacts with mitochondria protein, disrupts the electron transfer 
process, and generate reactive oxygen species contributing to the loss of synaptic function and 
plasticity, which are increasingly recognized as major mechanisms responsible for memory loss 
in AD.  In the nervous system, a synapse is a structure that permits a neuron (or nerve cell) to 
pass an electrical or chemical signal to another cell (neural or otherwise).  Therefore, 
understanding the role of mitochondrial abnormalities in the pathogenesis is important to develop 
the efficient tools for early diagnosis, and for the design of new therapeutic strategies aimed to 
preserve/ameliorate mitochondrial function. 
 
Cerebellum is two-size mounds of folded tissue located at the top of the brain stem and 
back bottom of the brain, the cerebellum is the guru of skilled and coordinated movement.  
Hippocampus located deep within the brain, it processes new memories for long term storage.  It 
is among the first functions to falter in AD.  The cerebral cortex is the outermost layered 
structure of neural tissue of the cerebrum (brain), in humans and other mammals.  It covers the 
cerebrum, and divides into two cortices, along the sagittal plane, covering the left and 
right cerebral hemispheres. The cortex plays a key role in memory, attention, perceptual 
awareness, thought, language, and consciousness.  It consists of up to six horizontal layers, each 
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with a different composition in terms of neurons and connectivity.  The human cerebral cortex is 
2 to 4 millimeters (0.079 to 0.157 in) thick.  It is referred to as grey matter as it consists of cell 
bodies and capillaries and contrasts with the underlying white matter, which mainly composes of 
the white myelinated sheaths of neuronal axons (Figure 2.2). 
 
Figure ‎2.2  Location of cerebellum, hippocampus and cortex in human brain anatomy. 
 
Pharmacokinetics (PK) is the study of drug disposition in the body and focuses on the 
changes in drug plasma concentration.  For any given drug and dose, the plasma concentration of 
the drug will rise and fall according to the rates of three processes: absorption, distribution, and 
elimination.  Absorption of a drug refers to the movement of drug into the bloodstream, with the 
rate dependent on the physical characteristics of the drug and its formulation.   Elimination of a 
drug from the blood relies on two processes biotransformation or metabolism of a drug to one or 
more metabolites, primary in the liver; and the excretion of the parent drug or its metabolites, 
primary by the kidneys.  
Drug distribution in pharmacology is a branch of pharmacokinetics which refers to the 
movement of a drug to and from the blood and various tissues of the body (for example, fat, 
muscle, and brain tissue).  After a drug is absorbed into the bloodstream, it rapidly circulates 
through the body.  As the blood recirculates, the drug moves from the bloodstream into the 
body's tissues.  Each organ or tissue can receive different doses of the drug and the drug can 
remain in the different organs or tissues for a varying amount of time.  The distribution of a drug 
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between tissues is dependent on vascular permeability, regional blood flow, cardiac output 
and perfusion rate of the tissue, and the ability of the drug to bind tissue and plasma proteins and 
its lipid solubility.  The pH partition plays a major role as well.  The drug is easily distributed in 
highly perfused organs such as the liver, heart and kidneys.  It is distributed in small quantities 
through less perfused tissues like muscle, fat and peripheral organs.  The drug can move from the 
plasma to the tissue until the equilibrium is established (for unbound drug present in plasma).  
Understanding how drugs behave in a biological system is a subject of prime importance in the 
treatment of various diseases.  
For systemic drug administration in research, the drugs are generally administered in 
mice through three main routes that include oral gavage, intravenous injection, and 
intraperitoneal injection.  In oral gavage, the drug in the form of solution is administered directly 
into the lower esophagus or stomach by the use of feeding needle.  The feeding needle has a bulb 
tip which prevents the rupture of delicate tissues during the drug administration.  The maximum 
volume that can be fed by oral gavage is 10 mL/Kg body weight of the mice.  Intraperitoneal (IP) 
injection of drug is one of the most frequently performed drug administration methods in mice.  
In this method the drug in the form of the solution is injected into the peritoneal cavity, a space 
that surrounds the abdominal organs.  A small and thin needle is inserted into the abdominal 
cavity in the lower right quadrant to avoid the puncture of cecum and urinary bladder with the 
needle.  For IP injection the volume of drug solution should not exceed 2 mL in an adult mouse.  
Intravenous (IV) injection is used to administer the drug solution directly in the blood through 
veins.  The vein in the tail of a mouse functions in thermoregulation and dilates on the rise in 
body temperature.  Thus application of heat to the tail of the mouse causes venodilation making 
the veins easily accessible for IV administration. The maximum volume of drugs administration 
through IV should not exceed 0.5 mL in an adult mouse.  The drugs administered through oral 
gavage and IP injections first diffuse into the blood stream.  The blood then transports and 
distributes the drugs in various tissues in the body. 
Elimination half-life (t1/2) is time required to reduce the plasma drug concentration by 
50%.  It can be calculated from the elimination rate constant, but it is usually determined from 
the plasma drug concentration curve.  Figure 2.3 shows a standardized drug plasma 
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concentration curve over time after oral or iv administration of a typical drug.
37
  The Y-axis is a 
linear scale of drug plasma concentration, often in μg/mL or mg/L, and the X-axis is a time scale, 
usually in hours. Parameters of the plasma drug concentration curve are the maximum 
concentration (Cmax), the time needed to reach the Cmax (Tmax).  A measure of the total amount of 
drug during the time course is given by the area under the curve (AUC).  These parameters are 
useful for comparing the bioavailability of different pharmaceutical formulations or of drugs 
given by different routes of administration.  To determine bioavailability, F, the AUC of the oral 
administration AUCpo, is divided by the AUC of the intravenous administered drug, AUCiv. 
Bioavailability (F) = AUCpo / AUCiv 
 
Figure  2.3  A standardized drug plasma concentration curve over time after oral administration 
(po) or intravenous (iv) of a typical drug.
37
 
 
Bioavailability is defined as the fraction (F) of the administered dose of a drug that 
reaches the systemic circulation in an active form.  The oral bioavailability of a particular drug is 
determined by dividing the AUC of an orally administered dose of the drug by the AUC of an 
intravenously administered dose of the same drug.  Intravenous administration of a drug provides 
the greatest possible bioavailability, and this method is defined to yield a bioavailability of 1 (or 
100%).  The bioavailability of drugs administered via other routes can be determined in the same 
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manner as the bioavailability of drugs administered orally.  The bioavailability of orally 
administered drugs is of particular concern because it can be reduced by many pharmaceutical 
and biologic factors.  Pharmaceutical factors include the rate and extent of tablet disintegration 
and drug dissolution.  Biological factors include the effect of food, which can sequester or 
inactivate a drug, the effect of gastric acid, which can inactivate a drug; and the effects of gut and 
liver enzymes, which can metabolize a drug during its absorption and first pass through the liver.  
The following two steps are often used to calculate the area under the curve (AUC)
38
:  (i) 
Calculate area of each trapezoid; and (ii) Sum all trapezoid areas to get AUC.  
 
The equation to calculate the area of trapezoid is when the curve in an increasing trend: 
   
  
The following equation is applied when the curve in a decreasing trend: 
 
 
 
C denotes drug concentration. 
t  denotes time. 
The subscript refers to the sample number. 
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2.3 Results and discussions 
 
2.3.1 CP2 distribution in neuronal cells and mouse brain region collection. 
 
CP2 in the cells or in the tissues was determined by plotting a calibration graph with the 
ratios peak areas of CP2 to BTA vs. molar ratios of CP2 to BTA as mentioned in the 
experimental section of this chapter.  The calibration graph for CP2 is shown in Figure 2.4. 
 
 
 
Figure ‎2.4  Correlation of ratios peak areas of pure CP2 and authentic BTA from HPLC 
chromatogram and molar ratios of pure CP2 and authentic BTA injected.   
Solutions of 100 μL of various concentrations of pure CP2 and authentic BTA were injected into 
an HPLC, the peak areas corresponding to CP2 and BTA were integrated from the HPLC 
chromatogram, and the ratios of the peaks were obtained. The results of the ratios of HPLC peak 
areas and the ratios from CP2 and BTA concentrations were plotted, and a linear correlation line 
was obtained from the graph. 
 
The amount of CP2 in the cell or tissues extract was calculated by determining the peak 
areas ratio of CP2 to BTA and determining the number of moles CP2 from the correlation  
graphs, as the number of moles BTA added to the cell and tissue extract was known.  HPLC 
chromatograms of the cells and tissues extract injected with a known amount of BTA showed a 
peak at 17 minutes which had the same retention time compared to the authentic CP2 as shown 
 60 
in Figure 2.5. The representative mass spectrum of eluant corresponding to the peak at 17  
minutes is highlighted in Figure 2.6. 
 
 
Figure  2.5  Representative HPLC chromatograms.  A is the HPLC chromatogram of the brain 
extract with known amount of BTA.  B is the HPLC chromatogram of 1:1 mol ratio of BTA and 
pure CP2.  C is the HPLC chromatogram of the control (brain tissue without CP2). The peak at 
17 minutes retention time in A had the same mass as pure CP2 which was confirmed by mass 
spectrometry.  
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Figure  2.6  Mass spectrum of the eluant corresponding to the peak at 17 minutes (of Figure 
2.5A) and is identical to pure CP2. 
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The results of CP2 distribution in subcellular fractions: crude nuclear, heavy 
mitochondria (HM) and light mitochondria (LM) are shown in Figure 2.7.  CP2 was found at 
mitochondria and shown to accumulate mostly in the heavy mitochondria fraction followed by 
light mitochondria fraction and least to accumulate in the crude nuclear fraction.  
 
 
 
Figure  2.7  CP2 concentration (μM/mg) in subcellular fractions: crude nuclear, heavy 
mitochondria and light mitochondria. 
 
After knowing that CP2 targets the mitochondria in cells, the next question we would like 
to address was that how much CP2 accumulated within each vital organ in mice.  Therefore, 
specific brain region including cerebellum, hippocampus, cortex and whole brain were harvested 
from two of the adult mice wild type (WT, C75/Blc) and APP/PS1 (A/P, transgenic).  Each tissue 
was isolated into three fractions: heavy mitochondria, light mitochondria and the crude nuclear.  
The distribution of CP2 (nM/mg) of tissue fractionation and brain regions in transgenic (A/P, 
APP/PS1) and wild type (WT, C75/Blc) mouse are highlighted in Figure 2.8 and Figure 2.9. 
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Figure  2.8  CP2 concentrations (nM/mg) in APP/PS1 (A/P, transgenic) mouse and wild type 
(WT, C75/Blc) mouse brain tissue fractionation.  
 
In both A/P and WT mouse, the brain tissue with the largest CP2 concentration was the 
heavy mitochondria, whereas crude nuclear had the smallest amount of CP2.  Light mitochondria 
had less amount of CP2 than heavy mitochondria but more than the crude nuclear fraction.  The 
hippocampus is a brain area critical for learning and memory, is especially vulnerable to damage 
at early stages of AD.  Interestingly, hippocampus area is the brain region which has the greatest 
amounts of CP2 concentration in both A/P and WT mouse.  The distribution of CP2 in the mouse 
brain regions suggests its efficacy to penetrate the blood brain barrier, which is generally 
difficult in cases of many drugs.   
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Figure  2.9  CP2 concentrations (μM/mg) in different brain regions of APP/PS1 (A/P, transgenic) 
mice and  wild type (WT, C75/Blc) mice.  
 
Inside the mitochondrion is a group of proteins that carry electrons along four chain 
reactions (Complexes I-IV), resulting in energy production.  This chain is known as the electron 
transport chain (ETC).  Mitochondria are essential organelles for neuronal survival and function 
since it produces more than 90% of the cellular adenosine triphosphate (ATP) in neurons.  
Extensive literature exists supporting a causative role of mitochondrial dysfunction in 
neurodegenerative disease pathogenesis including the AD.  Complex I, the first step in ETC, was 
known as the most common site for mitochondrial abnormalities. 
Notably, our latest results revealed that CP2 direct inhibits complex I of mitochondria 
leading to restriction in energy production, increasing in AMP/ATP ratio, upregulating of 
activated protein kinase (AMPK), inhibition of GSK-3β and reduction of hyperphosphorylated 
tau.  Moreover, our data suggests that 13 months of treatment CP2 restores axonal trafficking 
leading to improve cognitive and behavior phenotype in multiple animal models of FAD.  (These 
experiments were done by Dr. Eugenia Trushina’s group at Mayo Clinic, the data are not shown 
here and the results are being formulated into a manuscript to be submitted). 
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2.3.2  Distribution of TP70 in various organs. 
To examine the tissue distribution of TP70 in different organs, a dose of 25 mg/Kg of 
TP70, was administered to the male, 3-month old WT C57BL/6NHsd (Harlan) mice by iv 
administration.  TP70 in various tissues was determined by plotting a calibration graph with the 
ratios of peak areas of TP70 to 4-methoxyphenol vs. molar ratios of TP70 to 4-methoxyphenol  
as mentioned in the experimental section of this chapter.  The calibration graph for TP70 is 
shown in Figure 2.10.  
 
 
 
Figure  2.10   Correlation of ratios peak areas of authentic 4-methoxyphenol and pure TP70 from 
HPLC chromatogram and molar ratios of TP70 and 4-methoxyphenol  injected.   
 
Solutions of 100 μL of various concentration of authentic TP70 and pure 4-
methoxyphenol were injected into an HPLC, the peak areas corresponding to TP70 and 4-
methoxyphenol were integrated from the HPLC chromatogram, and the ratios of the peaks were 
obtained.  The results of the ratios of HPLC peak areas and the ratios from TP70 and pure 4-
methoxyphenol concentrations were plotted, and a linear correlation line was obtained from the 
graph. 
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Figure  2.11   Representative HPLC chromatograms.  A is the HPLC chromatogram of 1:1 mol 
ratio of 4-methoxyphenol and pure TP70.  B is the HPLC chromatogram of the lungs extract 
with a known amount of 4-methoxyphenol.  C is the HPLC chromatogram of the control (lungs 
without TP70). The peak at 30 minutes retention time in B has the same mass as pure TP70 
which was confirmed by mass spectrometry.  
 
The amount of TP70 in the tissues extract was calculated by determining the peak areas 
ratio of TP70 to 4-methoxyphenol and determining the number of moles of TP70 from the 
correlation graphs, as the number of moles of 4-methoxyphenol added to the tissue extract was 
known.  HPLC chromatograms of the tissues extract injected with a known amount of 4-
methoxyphenol  showed a peak at 30 minutes which had the same retention time compared to the 
authentic TP70 as shown in Figure 2.11. The representative mass spectrum of eluant 
corresponding to the peak at 30 min is highlighted in Figure 2.12. 
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Figure  2.12    Mass spectrum of the eluant corresponding to the peak at 30 minutes (of Figure 
1.11B) which is identical to pure TP70. 
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The summarization amounts of TP70 in various organs for distribution study and the 
half-life values are shown in Table 2.1 and Figure 2.13.   
Table  2.1   Results of PK study of TP70 (25 mg/Kg body weight; iv route; n = 3) and 
 distribution in various organs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2.13   Results of PK study of TP70 (25 mg/Kg body weight; iv route; n = 3) and 
distribution in various organs.  Each bar represents the average concentration of TP70 measured 
from 3 mice and is provided with (±) standard error. 
Time (hr) 
Average concentrations of TP70 (mg/L) 
Brain Heart Liver Lungs Kidneys Intestine Spleen 
0.5 18.6 ± 1.9 10.9 ± 0.65 13.4 ± 2.8 11.8 ± 1 16.7 ± 1.4 12.3 ± 3.3 11.3 ± 0.4 
1 12.5 ± 1 0.9 ± 0.38 18.4 ± 4.9 5.3 ± 2.3 11.2 ± 1.3 8.8 ± 1.9 7.8 ± 1.6  
2 8.5 ± 0.2 0.2 ± 0.04 5.7 ± 1.8 3.8 ± 1.3 9.9 ± 2 3.5 ± 2.2 2.5 ± 1.98 
4 3.6 ± 0.4 0.03 4.9 ± 1.4 2.8 ± 0.7 7.2 ± 3.7 2.4 ± 0.28 0.8 ± 0.43 
6 2.5 ± 0.4 0.01  2 ± 0.8 0.6 ± 0.5 6 ± 1.4 0.2 ± 0.25 0.15 ± 0.08 
24 1.12 ± 0.08 0 0 0 0.8 ± 0.6 0 0 
t1/2 (hr) 1.36 0.6 2 1.57 4.2 1.5 1.3 
Total 
mass of 
TP70 (µg) 
12 1.2 10.1 0.9 7.1 2.6 1.1 
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In 0.5 h from the iv administration of the drug, TP70 was detected in the major organs 
including brain, heart, liver, lungs, intestine, spleen and kidneys.  Brain had the highest 
distribution of TP70 with the respective concentration of 18.6 (mg/L) which implies the good 
penetration of the drug through the blood brain barrier.   Kidneys, liver, intestine, lungs, spleen 
and heart were found to have 16.7 (mg/L), 13.4 (mg/L), 12.3 (mg/L), 11.8 (mg/L), 11.3 (mg/L) 
and 10.9 (mg/L), respectively.  The amount of TP70 gradually decreases from 0.5 h to 6 h in 
most of the organs with the except of heart which has the concentration of TP70 dramatically 
change from 0.5 h to 1 h.  In 24 h time of the drug administration,  the amount of TP70 decreases 
to 1.12 (mg/L) in brain and 0.8 (mg/L) in kidneys, whereas heart, lungs, intestine, spleen and 
liver had no detectable amount of TP70 in 24 hours.  These results indicate that TP70 
accumulates in the brain in effective quantity and with half-life of 1.36 hours in brain. 
The average weight of each mouse is 25 g; therefore, the ideal amount of TP70 
administered to each mouse is 625 (µg).  After organs extraction and quantification, total mass of 
TP70 distributed in brain, heart, liver, lungs, kidneys, intestine and spleen is 35 (µg).  This result 
indicate that TP70 can be absorbed, distributed to major tissues, and metabolized in various 
tissues or excreted out from the body of mice.   
 
2.3.3  Pharmacokinetic (PK) and bioavailability of TP70 in plasma from the 
intravenous (iv) and oral gavage (po) administration. 
Table 2.2 and Figure 2.14 summarize results of PK and bioavailability of TP70 in 
plasma from the iv and po administration.  
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Table  2.2  Results of PK study of TP70 (25 mg/Kg body weight; oral gavage and iv routes;  
n = 3) in plasma. 
Time (min) 
Average concentration of TP70 in plasma (mg/L) 
po route iv route 
5 0 16.6 ± 6.1 
15 2.8 ± 0.09 10.2 ± 4 
30 3.9 ± 0.14 8.2 ± 3.5 
60 6.9 ± 0.17 3.7 ± 0.8 
120 4.2 ± 0.19 2.02 ± 0.6 
240 2.4 ± 1.37 1.8 ± 0.5 
360 1.2 ± 0.23 0.9 ± 0.3 
AUC (mg.min/L) 678 989 
F 0.68 1 
t1/2 (h) 2.05 1.06 
 
 
Figure  2.14  Results of PK study of TP70 (25 mg/Kg body weight; oral gavage and iv routes; n  
= 3) in plasma.  Each bar represents the average concentration of TP70 measured from 3 mice 
and is provided with (±) standard error. 
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In 5 minutes from the iv administration of the drug, TP70 was detected in plasma with 
the concentration of 16.6 (mg/L); however, no drug was found in plasma in 5 min when using 
the po route.  For the iv route, at first the drug concentration reduce quickly from 16.6 (mg/L) at 
5 min to 3.7 (mg/L) at 1h; then, it is slowly decreasing to 0.9 mg/L after 6 h of the drug 
administration.  In contrast, there is a quick increase from 15 min to 1 h with the TP70 
concentration of 2.8 (mg/L) and 6.9 (mg/L) when po administration.  After reaching the highest 
concentration of TP70 at 1 h, TP70 was found decrease steadily from 1 h to 6 h. These results 
show that TP70 has good clearance property along with the values of area under the curve 
(AUC) and bioavailability (F) point out that the drug can be administered for efficacy evaluation 
in vivo. 
 
2.4  Conclusion 
 
Distribution of CP2 in neuronal cultures and mouse brain region collection were studied.  
The results show that CP2 targets mitochondria and has the highest concentration in 
hippocampus which is one of the first regions of the brain to suffer the damage in Alzheimer’s 
disease.  Identification of the early molecular mechanisms underlying AD is of great important in 
order to develop efficient methods for diagnosis and therapeutic intervention.  
 
Pharmacokinetics and  bioavailability of compound TP70 were determined.  Area under 
the curve and bioavailability value F were calculated, and data show that TP70 has a good PK 
profile and bioavailability.  Pharmacodynamics study should be carried out.  
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2.5 Experimental  
 
2.5.1  Synthesis of CP2.
5-6
 
 
CP2 was synthesized in four steps (Scheme 2.1).  4-Hydroxy-6-methyl-2-pyrone and (S)-
perilaldehyde which are commercial available were refluxed for 24 hours in the presence of  L-
Proline and ethyl acetate to afford a single diastereoisomer tricyclic pyrone 46 in 78 % yield.  
Selective hydroxylation of the terminal double bond in 46 was carried out by hydroboration 
followed by oxidation to yield alcohol 47 in 68 % yield.  Mesylation of the alcohol 47 was 
achieved by treating alcohol with triethyl amine and methanesulfonyl chloride to afford 48 in 95 
% yield.  Mesylate 48 and adenine were taken together and heated in distilled dimethylacetamide 
(DMA) at 150 
o
C for 8 hours.  Column chromatographic separation using methylene chloride, 
ethyl acetate and methanol gave CP2 in 20% yield.  
 
 
Scheme  2.1  Synthesis of CP2. 
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(5aS,7S)-7-Isopropenyl-3-methyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1] 
benzopyran (46) 
  
 
 
 
To a solution of 20.0 g (158 mmol) of 4-hydroxy-6-methyl-2-pyrone in 0.8 L of ethyl 
acetate under argon at room temperature was added 24.0 g (0.158 mol) of (S)-(-)- perilaldehyde 
and 7.0 g (60.0 mmol) of L-proline.  The reaction mixture was heated to reflux for 24 h.  The 
progress of the reaction was monitored using TLC using hexane and ethyl acetate as a 
developing solvent.  The reaction mixture was washed with water and brine.  The water layer 
was extracted two times with ethyl acetate.  The combined organic layer was dried with 
anhydrous sodium sulfate, filtered and concentrated.  Purification was carried out by 
crystallization using ethyl acetate as a solvent to give a yellow solid of 46 in 78% yield.  [α]22D = 
+31.90 (c 0.75, CHCl3);  
1
H NMR (CDCl3) δ 6.1 (s, 1H, C10H), 5.72 (s, 1H, C4H), 5.1 (dd, J = 
11, 5 Hz, 1H, C5a H), 4.75 (m, 1H, =CH), 4.73 (m, 1H, =CH), 2.48 (ddd, J = 14, 4, 2.4 Hz, 1H), 
2.22-2.02 (m, 3H), 2.19 (s, 3H, C4-Me), 1.88-1.72 (m, 2H), 1.74(s, 3H, MeC=), 1.31 (ddd, J = 
25, 12.8, 4 Hz, 1H);  
13
C NMR (CDCl3)  δ 163.4, 162.6, 161.7, 147.9, 132.3, 109.8, 109.6, 99.9, 
97.5, 79.4, 43.6, 40.0, 32.5, 32.1, 20.9, 20.3.; MS FAB, m/z 259 (M + H
+
). 
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(5aS,7S)-7-[(1R) and (1S)-2-Hydroxy-1-methylethyl]- 3-methyl-1H,7H-5a,6,8,9- tetrahydro-
1-oxopyrano[4,3-b][1]benzopyran (47) 
 
 
 
To a cold solution (0 ºC) of 5.0 g  (19.0 mmol) of 46 in 200 mL of distilled THF under 
argon, was added 11.6 mL (11.6 mmol) of BH3•THF complex (1.0 M in THF).  After stirring the 
solution at 0 ºC for 3 h, gradually warmed up to room temperature and stirred for another 15 h. 
Cooled to 0 ºC and 20 mL of 0.1 % aqueous NaOH and 15 mL of 30% hydrogen peroxide were 
added.  The solution was stirred for 2 h, diluted with NaHCO3, and extracted three times with 
ethyl acetate.  The combined organic layer was washed with 100 mL of brine, dried (MgSO4), 
concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and 
ethyl acetate as eluents to give 3.27 g (68% yield; based on reacted 46) of 47 as a mixture of two 
diastereomers at C12 (1:1; based on 
13
C NMR spectrum) and 0.5 g (10 % recovery) of 46.         
1
H NMR (CDCl3) δ 6.08 (s, 1H, C4H), 5.71 (s, 1H, C10H), 5.07 (t, J = 5.2 Hz, 1H, C5aH), 3.62 
– 3.52 (m, 2H, CH2O), 2.46 (m,1H), 2.19 (s, 3H, Me), 2.13 – 1.99 (m, 2H), 1.73 – 1.51 (m, 3H), 
1.19 – 1.12 (m, 2H), 0.92 (d, J = 7 Hz, 3H, Me);  13C NMR (CDCl3)  (two diastereomers) δ 
163.5, 162.8, 161.6, 133.0, 109.0, 100.0, 97.4, 79.7, 79.6, 65.6, 39.9, 39.8, 39.4, 37.2, 37.1, 36.9, 
32.4, 32.3, 31.1, 30.4, 28.5, 20.1, 13.2 (Me for a diastereomer), 13.1 (Me for another 
diastereomer). 
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(5aS,7S)-3-Methyl-7-[(1R) and (1S)- 2-(methanesulfonyloxy)-1-methylethyl]-1H,7H- 
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (48) 
 
 
 
To a cold (0 ºC) solution of 7 g (25.0 mmol) of 47 in 200 mL of distilled methylene 
chloride under argon, were added 10.7 mL (76.0 mmol) of distilled triethylamine and 3 mL (40.0 
mmol) of methanesulfonyl chloride.  The solution was stirred for 4 h at room temperature, 
diluted with NaHCO3, and extracted three times with methylene chloride. The combined 
dichloromethane layer was washed with brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluents to 
give 6.65 g (95% yield) of 48 as a mixture of two diastereomers (1:1; based on 
13
C NMR 
spectrum).  
1
H NMR (CDCl3)  δ 6.08 (s, 1H, C4H), 5.71 (s, 1H, C10H), 5.06 (m, 1H, CHO), 4.18 
– 4.08 (m, 2H, CH2O), 3.03 (s, 3H, MeS), 2.49 (d, J  = 2.8 Hz, 1H), 2.19 (s, 3H, Me), 2.14  –  
1.11 (m, 7H), 0.98 (d, J = 6.8 Hz, 3H, Me); 
13
C NMR (CDCl3) δ 163.2, 162.4, 161.7, 132.1, 
109.6, 105.2, 99.8, 79.2, 79.1, 72.3, 38.9, 37.5, 37.4, 37.3, 37.2, 36.9, 32.2, 32.1, 30.8, 28.6, 20.2, 
13.3 (Me for a diastereomer), 13.2 (Me for another diastereomer). 
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(5aS,7S)-7-[(1R) and (1S)- 2-(N3-adenyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9- 
tetra hydro-1-oxopyrano[4,3-b][1]benzopyran (CP2) 
 
 
 
In a round bottom flask fitted with a reflux condenser, taken 6.0 g of mesylate 48 (16.9 
mmol) and 2.5 g of adenine (18.6 mmol) together and vacuum dried, purge argon and added 150 
mL of distilled DMA and heated  at 170 - 180 °C for 8 h.  TLC showed no starting material.  The 
reaction was cooled to 25 °C and vacuum distilled to remove DMA.  Column chromatographed 
on silica using a gradient mixture of methylene chloride, ethyl acetate and methanol as eluent to 
afford CP2 in 20% yield.  
1
H NMR (CDCl3)   δ 8.07 (s, C8 H of adenine), 7.98 and 7.97 (2 s, 1H, 
C2H of adenine; 2 diastereomers), 6.10 (s, 1H, C10H), 5.72 and 5.71 (2s, 1H, C4H), 5.02 (m, 
1H, C5aH), 4.50 (dd, J = 14, 7 Hz, 1H, CHN), 4.08 (2dd, J = 14, 8 Hz, 1H, CHN; 2 
diastereomers), 2.46 (m, 2H), 2.20 and 2.19 (2s, 3H, Me; 2 diastereomers), 2.10 – 1.22 (a series 
of m, 6H), 0.91 (d, J = 47.0 Hz, 3H, Me). 
13
C NMR (CDCl3)  (2 diastereomers) δ 163.2 and 
163.1, 162.4, 161.7, 154.4,154.0, 150.7, 142.3, 131.7 and 131.6, 121.0, 199.8, 99.7, 97.3, 79.0, 
78.8, 54.5 and 54.4, 38.9, 38.1 and 38.0, 37.1 and 36.9, 36.1, 32.0 and 31.9, 30.7, 27.6, 20.1, 
13.3 and 13.2.  
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2.5.2  Synthesis of TP70. 
 
TP70 was synthesized as shown in Scheme 2.2.  Hydroboration-amination of compound 
46 by treating with BH3•THF in dry tetrahyrofuran (THF) at 0 
o
C for 2 hours and then warming 
up to room temperature for another 12 hours followed by refluxing with hydroxylamine-O-
sulfonic acid (HSA) furnished tricyclic pyrone amine 49 in 50% yield.  Treatment of tricyclic 
pyrone amine 49 with 4-hydroxybenzaldehyde in methanol followed by sodium 
cyanoborohydride and acetic acid afforded TP70 in 56% yield.  
 
 
Scheme  2.2  Synthesis of TP70. 
 
(5aS,7S)-7-[(1R) and (1S)-2-Amino-1-methylethyl)-3-methyl-1H,7H-5a,6,8,9-
tetrahydro-1- oxopyrano[4,3-b][1]benzopyran (49)  
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A solution of 10 mL (10.0 mmol) of BH3•THF complex (1.0 M in THF) was added dropwise 
to a cold (0 
o
C) solution of 5.0 g (19.4 mmol) of compound 46 in 100 mL of THF, under argon.  
After stirring the solution at 0 
o
C for 2 h and 25 
o
C for 12 h, the borane solution was added to 3.3 g 
(29.2 mmol) of hydroxylamine-O-sulfonic acid via a cannula followed by the addition of 20 mL of 
chloroform.  The reaction mixture was heated to reflux for 7 h, cooled to 25 
o
C, diluted with 300 mL 
of ethyl acetate, and extracted with 2 N HCl (100 mL x 2).  The combined HCl layer was washed 
three times with ethyl acetate (100 mL each), basified carefully with 5% sodium carbonate until pH = 
9 ~ 10, and extracted three times with dichloromethane.  The combined dichloromethane layer was 
washed with brine, dried (anhydrous Na2SO4), and concentrated to give 2.7 g (50% yield) of 
compound 49, whose 
1
H and 
13
C NMR spectra are identical to that reported previously from our 
group.
36 
 
(5aS,7S)-3-Methyl-7-[(1R) and (1S)-1-(4-hydroxybenzylamino)propan-2-yl]-1H,7H- 
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (TP70) 
 
 
 
A solution of 3.2 g (11.6 mmol) of amine 49 and 1.1 g (8.8 mmol) of 4-methoxy 
benzaldehyde in 40 ml of dry MeOH was stirred under argon at 25 
o
C for 12 h.  To it were added 
acetic acid (5 drops) and 2.47 g (39 mmol) of NaBH3CN.  After stirring for 1 h, the reaction 
solution was with 200 mL of 5% aqueous ammonium hydroxide and extracted three times with 
dichloromethane.  The combined organic layers was washed with brine, dried (MgSO4), 
concentrated, and crystallized in ethyl acetate to give 2.5 g (57% yield) of light-yellow solid 
TP70 whose 
1
H and 
13
C NMR spectra are identical to that reported previously from our group.
7 
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2.5.3  CP2 treatments in neuronal cultures and mouse brain region collection. 
These following experiments were performed by Dr. Eugenia Trushina and Dr. Liang 
Zhang at Mayo Clinic.  
 
Primary cortical neurons were isolated from mouse pups which have 15 – 17 embryonic 
day (E) and plated at a density of 6 x 10
6
 cells per plate in 10-cm plate.  The cells were cultured 
for 5 days before they were treated with 2 µM of CP2 for 24 hrs.  To it, 0.01% of DMSO was 
used as vehicle in control cultures.  Media were aspirated off from the culture at the end of the 
treatment and the cells were washed twice in ice-cold PBS buffer before collected in 0.6 mL of 
MIBA buffer for mitochondria isolation.  
 
A dose of 50 mg/kg (mice body weight) of CP2 as trifluoroacetic acid (TFA) salt 
dissolved in water was fed to two of the adult mice wild type (WT, C75/Blc) and APP/PS1 (A/P, 
transgenic) up to two months before they were sacrificed.  One other mice (WT) was served as 
the control.  Mice were sacrificed by cervical dislocation.  Specific brain region including 
cerebellum, hippocampus, cortex and whole brain were harvested from one hemisphere of the 
mice brain under the microscope in PBS buffer at room temperature and stored the isolated tissue 
on ice for mitochondria isolation.   
 
Mitochondria isolation process 
 
The tissue were suspended in MIBA buffer containing 10 mM Tris-HCl, pH 7.4, 1 mM 
EDTA, 0.2 M D-manitol, 0.05M sucrose, 0.5 mM sodium orthovanadate, 1 mM sodium fluoride, 
1X complete protease inhibitors and phosphatase inhibitor.  The tissue was homogenized with 
the aid of a Teflon pestle and lysis was confirmed microscopically.  The crude nuclei were 
removed from the lysate by centrifugation at 500 rpm at 4 
o
C for 5 min.  The remaining 
supernatant was centrifuged at 8,000 rpm for 10 min at 4 °C, yielding the heavy mitochondrial 
(HM, pellet) and the light mitochondrial/cytosolic (LM, supernatant) fraction.   The HM pellet 
was washed twice with ice-cold MIBA buffer before it was resuspended in 0.3 mL of this buffer. 
 80 
   
2.5.4  TP70 administration and plasma collection. 
A dose of 25 mg/kg (mice body weight) of TP70 as trifluoroacetic acid (TFA) salt 
dissolved in 2% DMSO in 0.5% hydroxypropyl cellulose (HPC) was administered to the male, 3 
months old WT C57BL/6NHsd (Harlan) mice by oral (po) or intravenous injection (iv).  Cardiac 
blood collection was treated with ethylenediamine tetraacetic acid (EDTA).  About 250 μL 
plasma was collected from each mouse.  All the tissues and plasma collected were stored at -78 
0
C  until further analysis was carried. 
 
2.5.5  Extraction of CP2 and TP70 from the cells and the tissues. 
To the mitochondria fraction solution were added 3 mL of deionized water and 10 mL of 
9:1 mixture of ethyl acetate and 1-propanol.  Sodium bicarbonate (10 mg) was added to the 
mitochondria fraction solution and sonicated for 3 minutes.  The organic layer was separated 
from a separatory funnel.  The aqueous layer was extracted twice with 10 mL of a 9:1 mixture of 
ethyl acetate and 1-propanol.  The organic layers were combined, washed with 10 mL of brine, 
dried over anhydrous MgSO4, and concentrated to dryness on a rotary evaporator.  The residue 
was diluted with 1 mL of 1-propanol and filtered through a 0.2 µm filter disc (PTFE 0.2 µm, 
Fisherbrand) and analyzed using HPLC and mass spectrometry as described below. 
 
In case of TP70, organs were weighed and cut into small pieces.  The same procedure as 
CP2 extraction was then conducted. 
 
2.5.6  Quantification of CP2 and TP70 using HPLC 
  
HPLC analysis of CP2 and TP70 was carried out on a Varian Prostar 210 with a UV-Vis 
detector.  A C18 reverse phase column from Xper-chrom Aegis (S. No: 104117, 250 x 10 mm, 
10 micron) was used for both CP2 and TP-70. A flow rate of 10 mL/min and detection 
wavelength of 254 nm were used. A gradient elution of solvent A, containing deionized water 
and 0.01 % of trifluoroacetic acid, and solvent B, containing acetonitrile and 0.01 % of 
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trifluoroacetic acid, was applied for the analysis of CP2. A gradient elution of solvent A, 
containing deionized water  and solvent B, containing methanol was applied for the analysis of 
TP70. 
1,2,4,5-Benzenetetracarboxylic acid (BTA) or 4-methoxyphenol were used as an internal 
standard to quantify the amount of CP2 and TP70, respectively.   BTA does not undergo amide 
formation reaction with CP2 at ambient temperature because (i) –OH group in carboxylic acid is 
a poor leaving group and (ii) BTA has a pKa ~ 3 that is lower as compared to the pKa of the 
amine on the adenine moiety (pKa ~ 9.8) of CP2 resulting in a very small amount of free amine 
(nucleophile) in the equilibrium as shown in Scheme 2.3.  Moreover, the presence of 0.01% of 
trifluoroacetic acid (pKa = 0.52) in the solvents for HPLC regenerates BTA from its salt as. 
 
 
 
Scheme  2.3  Schematic representation of the regeneration of BTA from the salt of BTA with 
CP2. 
Solutions of 100 µL of various concentrations of pure CP2 and BTA or TP70 and 4-
methoxyphenol were injected into an HPLC instrument, the peak areas corresponding to CP2 and 
BTA or TP70 and 4-methoxyphenol were integrated from the HPLC chromatogram, and the 
ratios of the peaks were obtained.  The results of the ratios of the HPLC peak areas and the ratios 
from CP2 and BTA or TP70 and 4-methoxyphenol concentrations were plotted, and a linear 
correlation line was obtained from the graph (Figure 2.4 and Figure 2.10).  Hence, using this 
correlation diagram, the ratio of HPLC peak areas of CP2 and BTA or TP70 and 4-
methoxyphenol from cells or tissue extract, and added known amount of BTA to the cells or 
tissue extract, the amount of CP2 or TP70 in the cells or tissue extract was determined.  
 82 
Moreover, the eluant corresponding to the peak that has the same retention time as that of CP2 or 
TP70 from the injection of the cells or tissue extract was collected, and their masses were 
determined using mass spectrometer.  The mass spectrometer acquired from the collected peak of 
CP2 and TP70 from the cells or tissue extract were identical to that of pure CP2 and TP70 mass 
spectra.  The eluent corresponding to CP2 or TP70 peak from the HPLC was collected and 
injected into the mass spectrometer.  A mass of 394 corresponding to [M+H
+
] of CP2 was found 
in their mass spectra and the fragmentation pattern of this [M+H
+
] mass is similar to that of pure 
CP2 verifying the identity of CP2.  A mass of 382 and 404 corresponding to [M+H
+
] and 
[M+Na
+
] of TP70 were found in their mass spectra which is identical to that of pure TP70 
verifying the identity of TP70.  
 
To determine the volume or weight of cells, total DNA or protein content within the 
tissues or cell is normally chosen to normalize the data obtaining from any assay.  In the series of 
experiments had done for CP2, protein content within the cells or tissues is the most appropriate 
denominator, hence μM CP2 per mg of total protein found within the cell or tissue was chosen to 
normalize for the experiments.  This is performed by Dr. Liang Zhang at Mayo Clinic.  One may 
also normalize the result to wet weight of the tissue; however, since the mass of cells in cultures 
can not “weigh out” or obtain fixed volume after mitochondria isolation process, the most 
sensible approach would be using total protein content.   
 
The concentration of TP70 in the organs was obtained by finding the number of moles of 
TP70 in the given volume of the organs (assuming that mass of organs = volume of organs ~ 1). 
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Chapter 3. Synthesis of unnatural aminal acids for the preparation 
of novel tripeptidyl anti-viral inhibitors. 
 
3.1  Introduction 
 
With the emergence of the GII.4 Sydney strain of norovirus in 2012, the search for a 
therapeutic drug has become even more essential than previously thought.  Norovirus (NV) is 
detrimental to human way of life because contagious fecal particles can be transmitted several 
ways, like ingestion, direct contact, and through air, which are all easily permissible due to how 
interconnected our society is.  Therefore, once a person becomes contaminated, the virus will 
spread easily and affect those, especially in enclosed quarters, like that of cruise ships, hospitals, 
and school dormitories.  Often mislabeled as the stomach flu or food poisoning, this 
gastroenteritis-causing virus inflames the stomach and/or intestines while producing symptoms 
like diarrhea, fever, nausea, vomiting, body ache, et cetera.
1
  No medication currently exists, so 
anyone affected experiences the symptoms for an average three days; however, the elderly, 
immune deficient and young children will have a harder time recovering. In fact,  there are 
70,000 hospitalizations and over 800 deaths annually
2
, in the United States, alone.  Current 
therapeutics, such as Tamiflu, utilizes a small synthesized organic compound that inhibits the 
release of viral molecules into the surrounding environment of the body by targeting one of the 
virus’ surface proteins.  However, this medicine can only be used specifically for the influenza 
virus strain.  Therefore, it is important to create an anti-viral therapeutic to reduce casualties that 
occur from the various norovirus strains. 
  
Previous study in our group
3
 has discovered a novel, highly active tripeptidyl compound 
for broad-spectrum viral inhibition; however, oral bioavailability of this drug is poor.  Our 
research group is currently synthesizing the tripeptidyl analogue in three separate parts.  The 
amino acid utilizes the P1 and P2 parts for recognition of the norovirus cleavage site, while it 
includes P3 with the intention of bettering its bioavailability and aiding cell penetration (Figure 
3.1).  My work involved in the synthesis of the P3 unnatural amino acid for the preparation of a 
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novel  tripeptidyl compound.  The main focus is on increasing the hydrophilicity of the amino 
acid by incorporating polar hydroxyl groups which will help increase the oral bioavailability of 
the drug.  It has been found that several viruses, in fact, have conserved specificity for cleavage 
sites at the P1 and P2 sites, making this amino acid analogue a possible broad-spectrum 
therapeutic, capable of inhibiting the norovirus, SARS, HAV, and rhinovirus’ proteases.   
 
 
 
 
 
Figure  3.1  Generic tripeptidal protease inhibitor structure and the reversibility of the aldehyde 
warhead and cysteine residue at the active site of norovirus. 
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3.2  Background 
 
Noroviruses (NVs) are a non-enveloped, single stranded RNA with a positive sense 
genome belonging to the family of Calcivirdae.  It is 7.5 kBp and approximately 60 kDa.  Its 
mutation rate is very high, occurring on average of every two to three years.  The genome has 
been found to contain three open reading frames (ORFs) as shown in Figure 3.2.
4 
 
 
 
Figure  3.2  Norovirus Genome. 
 
Overall, there are five norovirus genogroups (GI, GII, GIII, GIV and GV), and they all 
vary slightly because the virus does not contain a proofreading mechanism, unlike that found in 
human DNA replication.  Viruses most commonly infecting humans belong to GI and GII.  In 
the non-structural proteins of the ORF1 (open reading frame 1), the norovirus genome contains 
the 3C-like protease (3CL).  This protease is important to the virus’ survival because it cleaves 
the non-structural proteins to form mature proteins, and therefore, an active virus that can be 
packaged and sent to infect other cells.  
 
According to previous studies
5,6
 the protease’s active site has conserved specificity 
among several strains of norovirus, which makes it an effective target spot for an anti-viral 
inhibitor. The 3CL protease normally cleaves the replicated peptide strand to produce functional 
proteins; therefore, by identifying the specific amino acid residues at the active site, the 
norovirus protease cannot cut necessary portions as the drug will competitively block that spot.   
The most important residue for the substrate specificity is a glutamine amino acid residue, and 
therefore, the P1 site of the inhibitor is a surrogate glutamine containing an aldehyde warhead 
that allows a nucleophilic attack by the thiol function of cysteine residue in norovirus 3CL 
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protease.  The P2 site, which is a leucine residue, is also important for recognition of the virus 
active site because it fits in the pocket created by the protease’s catalytic dyad. 
 
  Our efforts to create a new anti-NV drug focus primarily on the inhibition of NV 3C-like 
protease (NV3CL
pro
).  We recently reported a novel class of tripeptidal anti-Noroviral 
compounds which strongly inhibit NV3CL
pro
  in enzyme and cell based assay.
3
  Compound 50 
and 51 were found to be two of the most active compounds with IC50 0.14 μM; EC50 0.04 μM 
and IC50 0.21 μM; EC50 0.06 μM, respectively.  Compound 50 has an aldehyde warhead, a P1 
glutamine surrogate, a P2 leucine, a P3 L-1-napthylalanine and an N-terminal Cbz cap (Figure 
3.3). Compound 51 has similar structure to compound 50 except of the P3 has the benzyl 
funtionality group.  The warhead is the part of the molecule that is forming covalent bond with 
the enzyme (aldehyde function or ketoamide function).  Compound 50 and 51 also possess 
strong inhibitory against other viral strains in the caliciviridae, picornavirus, and coronaviridae 
viral families especially human rhino virus (HRV) and SARs.  The compounds also show 
minimal cell cytotoxicity.  These encouraging results prompted us to conduct an ongoing study 
to improve activity and bioavailability for the lead compounds which will be discussed in the 
following section. 
 
 
Figure  3.3  Chemical structure of compound 50 and 51. 
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3.3  Synthesis of P3 unnatural amino acids for the preparation of novel 
tripeptidyl compounds. 
 
We hypothesize that incorporating a polar hydroxyl group in the P3 part would help 
increase hydrogen bonding between the enzyme active site and the drug leading to a stronger 
binding and ultimately will help oral bioavailability of the drug.  In fact, computation docking of 
compound 50 with SARs protease enzyme (pdb file SARS-CoV-3CL) revealed that adding the  
meta hydroxyl group on the P3 L-1-napthylalanine of compound 50 can provide additional 
hydrogen bonding between the acid moiety of glutamic acid (Glu) and the OH (Figure 3.4 ).  
The docking results were supported by a single-crystal X-ray analysis of a complex of SARs-
3CL
pro
 and 50 (unpublished results).  This helps improve the binding affinity and reducing the 
partition coefficient value.  
 
 
Figure  3.4  Computational docking of compound 50 derivative (Napthylalanine-C3-OH) in 
complex with SARs protease enzyme (pdb file SARS-CoV-3CL). 
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Therefore, the P3 unnatural amino acid (Figure 3.5) for the preparation of a novel 
tripeptidyl compound is synthesized as shown in Scheme 1. 
 
 
 
Figure  3.5  Chemical structure of P3 [((S)-3-hydroxyphenylalanine)]
7
 unnatural amino acid. 
 
  
Following the reported procedure
7
, protection of 3-hydroxybenzaldehyde by using tert-
butyldimethylsilyl chloride in the presence of triethylamine and DMAP in dichloromethane at 
25
o
C for 2 hours to give 52 in 90% yield.  Aldehyde 52 was reduced by using sodium 
borohydride (NaBH4) in ethanol at 0 
o
C for 1 hour to obtain alcohol 53 in 93% yield.  
Bromination of compound 53 by using triphenylphosphine (PPh3) and NBS in CH2Cl2 at 25
o
C 
for 5 hours to give 54 in 70% yield.  Reaction of diethyl acetamidomalonte (55) with 54 in 
absolute ethanol in the presence of one equivalent of sodium ethoxide (NaOEt) led to the 
disubstituted malonyl diester 56 in 63% yield.  Diester 56 was saponified to afford the mono 
ester 57 in a 32% yield.  Decarboxylation of neat mono ester 57 occurred at 160 
o
C in vacuum 
within 10 minutes to give racemic 58a and 58b which was then resolved by using enzyme 
Subtilisin in DMSO to obtain 59a in 12 % yield.  The acetamide protecting group of compound 
59a will be removed by acid hydrolysis to give 60 (S)-3-hydroxyphenylalanine.  The final step 
was not done due to only a small amount of compound 59a was afforded which was not enough 
to continue for the final step. 
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Scheme  3.1  Synthesis of P3 unnatural amino acid. 
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3.4  Conclusion 
 
An unnatural amino acid was synthesized using the above method for the creation a novel 
tripeptidyl compound.  This simple synthesis method can also be used as a model method for the 
synthesis of other unnatural amino acids for preparation of novel tripeptidyl anti-viral inhibitors.  
After incorporating the synthesized P3 into P1 and P2 amino acids to form the tripeptidyl 
compound, a biological evaluation will be completed to test for bioactivity.  Moreover, structure-
activity relationship study will show if our estimations are correct and if we are headed in the 
right direction of improving our tripeptidyl compounds.  In addition, this compound will be also 
tested against other similarly structured viruses to determine whether our novel tripeptidyl 
compound can act as a broad-spectrum viral protease inhibitor. 
3.5  Experimental section 
 
3-(tert-Butyldimethylsilanyloxy)benzaldehyde (52) 
 
 
 
To a solution of 5.0 g (41 mmol) of 3-hydroxybenzaldehyde 
 
in 100 mL of distilled 
dichloromethane at 0 
o
C under argon, were added 11.5 mL of triethylamine, 0.75 g (6 mmol) of 
4-dimethylaminopyridine (DMAP), and 12.4 g (0.82 mol) of tert-butyldimethylsilyl chloride and 
the solution was stirred at 25 
o
C for 2 hours.  The reaction was diluted with 150 mL of diethyl 
ether and washed with 100 mL of saturated aqueous NH4Cl solution, 20 mL of water, and 20 mL 
of brine.  The organic layer was dried over anhydrous MgSO4, concentrated, and column 
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chromatographed on silica gel using a mixture of hexane and diethyl ether as an eluent to give 
8.72 g of product 52 (90.2% yield).  
1
H NMR  (CDCl3) δ 9.96 (s, 1H), 7.48 (m, 1H), 7.42 (t, J = 
7.81 Hz, 1H), 7.34 (m, 1H), 7.09 – 7.15 (m, 1H), 1.01 (s, 9H), 0.24 (s, 6H).  
 
3-tert-Butyldimethylsilyloxybenzyl alcohol (53) 
 
 
 
To the solution 52 (9.41 g, 39.8 mmol) in 100 mL of ethanol, sodium borohydride 
(NaBH4, 0.75g, 19.9 mmol) was added at 0 °C. The mixture was stirred at 0 °C for 1 hour.  The 
reaction solution was diluted with 200 mL of ether, washed with 50 mL aqueous.  The aqueous 
layer was extracted 2 times with ether (100 mL each time).  The combined organic layers were 
washed with brine, dried over anhydrous sodium sulfate, and concentrated to give 8.79 g of 
product 53 (92.6% yield).   
1
H NMR  (CDCl3) δ  7.22 (t, 1H, J = 7.81 Hz), 6.96 (d, 1H, J = 7.81 
Hz), 6.87 (s, 1H, J = 1.5 Hz), 6.75 - 6.80 (m, 1H), 4.65 (d, 2H, J = 5.5 Hz), 1.00 (s, 9H), 0.21 (s, 
6H).  
 
3-(tert-Butyldimethylsilyloxy)Benzyl Bromide (54) 
 
 
 
To a solution of compound 53 (8.79 g, 36.9 mmol),  triphenylphosphine PPh3 (14.5g, 
55.4 mmol) in distilled CH2Cl2 (100 mL), N-bromosuccinimide (NBS, 9.86 g, 55.4 mmol) was 
added at 0
 o
C.  The reaction was stirred under argon at room temperature for 5 hours. The 
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reaction was diluted with 50 mL water and extracted with CH2Cl2 (150 mL x 2).  The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated.  
The oily concentrate was column chromatographed on silica gel using a gradient mixture of 
hexane and diethyl ether as eluants to give 7.85 g of product 54 (70.8% yield).  
1
H NMR  
(CDCl3) δ  7.20 (t, 1H, J = 7.81 Hz), 6.96 (d, 1H, J = 7.7 Hz), 6.88 (t, 1H, J = 1.95 Hz), 6.75 – 
6.80 (m, 1H), 4.45 (s, 2H), 0.99 (s, 9H), 0.20 (s, 6H).  
13C NMR (CDCl3), δ  156, 139.3, 129.9, 
122.1, 121.0, 120.4, 33.6, 25.9, 18.4, –4.2.  MS (electronspray ionization) m/z 325 (M+Na
+
). 
 
Diethyl 2-acetamido-2-(3-(tert-butyldimethylsilyloxy)benzyl)malonate (56) 
 
 
 
Sodium (77.4 mg, 3.37 mmol) was dissolved in absolute ethanol (10 mL).  After the 
mixture was cooled down to 0 
o
C, diethyl acetamidomalonate 55 (0.73 g, 3.37 mmol) was added 
under argon.  Compound 54 (1 g, 3.33 mmol) in absolute ethanol (10mL) was added after 5 
minutes stirring at 0 
o
C.  The reaction mixture was refluxed for 6 hours.  Once cooled to room 
temperature, the solution was concentrated, and the crude was column chromatographed on silica 
gel using a gradient mixture of hexane and diethyl ether as eluants to give 0.94 g of product 56 
(64% yield).  
1
H NMR  (CDCl3) δ  7.11 (t, J = 7.81 Hz, 1H), 6.72 (d, J = 7.81 Hz, 1H), 6.60 (d, J 
= 7.03 Hz, 1H), 6.56 (br. s, 1H), 6.51 (s, 1H), 4.20 - 4.34 (m, 4H), 3.59 (s, 2H), 2.03 (s, 3H), 1.25 
- 1.34 (m, 6H), 0.98 (s, 9H), 0.18 (s, 6H).  
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2-acetamido-3-ethoxy-2-(3-hydroxybenzyl)-3-oxopropanoic acid (57) 
 
 
 
To a solution of compound 56 (0.7 g, 1.6 mmol) in 1 mL dioxane, was added NaOH 
(0.13 g, 3.2 mmol) in 1mL of 1:9 H2O:dioxane solution.  After 15 hours stirring at room 
temperature, the reaction mixture was acidified with 1 N HCl (pH = 3 – 4), and extracted with 
ethyl acetate.  Organic layers were dried with sodium sulfate, filtered and concentrated to give 
0.16 g of compound 57 (45% yield).  
1
H NMR  (DMSO-d6) δ  8.99 - 9.08 (s, 1H), 6.87 - 6.94 (m, 
1H), 6.58 - 6.63 (m, 1H), 6.45 - 6.49 (m, 1H), 6.39 - 6.44 (m, 1H), 3.84 - 4.08 (m, 4H), 1.78 (s, 
3H), 1.09 (t, 3H).  
 
Ethyl-2-acetamido-3-(3-hydroxyphenyl)propanoate (58a, 58b) 
 
 
 
Compound 57 (0.15 g, 0.52 mmol) was decarboxylated at 160
o
C under vacuo in 10 
minutes.  After cooling to room temperature, the crude was column chromatographed on silica 
gel using a gradient mixture of hexane and ethyl acetate as eluants to give 40 mg mixture of 58a, 
58b (30.5% yield).  
1
H NMR (CDCl3) δ 7.15 (t, J = 7.81 Hz, 1H), 6.71 - 6.77 (m, 1H), 6.65 - 
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6.68 (m, 1H), 6.31 (s, 1H), 6.05 (d, J = 7.42 Hz, 1H), 4.86 (td, J = 6.05, 7.81 Hz, 1H), 4.19 (q, J 
= 7.03 Hz, 2H), 3.02 - 3.14 (m, 2H), 2.02 (s, 3H), 1.25 (t, J = 7.22 Hz, 3H).   
 
 (S)-ethyl-2-acetamido-3-(3-hydroxyphenyl)propanoate (59a) 
 
 
 
 
To a solution of of 58a, 58b (40 mg, 0.16 mmol) in 1 mL of dimethyl sulfoxide (DMSO)  
was added deionized water (0.5 mL), and 1 N KCl (0.14 mL).  Subtilisin Carlsberg (1 mg) was 
dissolved in deionized water (0.5 mL) and  0.1. N KCl solution (80 μL).  The enzyme solution 
(0.3 mL) was added to the reaction and the mixture was stirred at 39 
o
C for 1 hour.  0.15 mL and  
50 μL of the enzyme solution was added to the reaction after stirring for 1 hour and 3 hours, 
respectively.  The reaction was diluted with deionized water (10 mL).  The aqueous layer was 
acidified with 1 N HCl to pH = 3, extracted three times with ethyl acetate (10 mL each time).  
Combined organic layers were washed with water, brine, dried with sodium sulfate, filtered and 
concentrated to give 4.2 mg of compound 59a (12 % yield). 
1
H NMR (DEUTERIUM OXIDE) δ 
7.11 - 7.20 (m, 1H), 6.73 - 6.79 (m, 1H), 6.69 - 6.73 (m, 1H), 6.65 - 6.70 (m, 1H), 4.36 - 4.43 (m, 
1H), 3.03 - 3.11 (m, 1H), 2.76 - 2.86 (m, 1H), 1.84 (s, 3H).  MS (electronspray ionization) m/z 
246 (M+Na
+
).   
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Appendices: 1H NMR, 13C NMR, and IR Spectra 
Compound 20 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 14 2009
Date Stamp May 14 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-91-DPPURE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
Br
OMe
KP-4-91-DPPURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
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0.15
0.20
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0.40
0.45
0.50
0.55
0.60
0.65
0.70
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n
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y
3.000.96
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Compound 20 
13
C NMR 
 
6/27/2012 3:30:36 PM
Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 13 2009 Date Stamp Jul 13 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-4-78-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 188 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent acetone Spectrum Offset (Hz) 11069.2324
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
MeO
Cl
CHO
O
Si
KP-4-78-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
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Compound 21 
1
H NMR 
 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 15 2009 Date Stamp Aug 15 2009
File Name C:\USERS\KESHAR\KP-4-115-FR-1-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 36 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 44.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
MeO OCHO
O
Si Cl
KP-4-115-FR1-PROTON.ESP
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.05
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Compound 21 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 16 2009 Date Stamp Jul 16 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-4-115-FR1-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 88 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
MeO
Cl
OCHO
O
Si
KP-4-115-FR1-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
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Compound 22 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 16 2009
Date Stamp Aug 16 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-117-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
MeO
O
Cl
OH
Si
KP-4-117-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
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0.50
0.55
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0.65
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5.8611.693.861.000.89
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Compound 22 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep 12 2009 Date Stamp Sep 12 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-80-FR2-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 4016 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4879.6978 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
MeO
Cl
OH
O
Si
KP-4-80-FR2-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
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Compound 19 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Sep 17 2009
Date Stamp Sep 17 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-31-QUINONE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 56 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
MeO
Br
Cl
KP-5-31-QUINONE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
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Compound 19 
13
C NMR  
 
 
 
6/27/2012 1:52:28 PM
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  7 2009 Date Stamp Oct  7 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-119-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 9152 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.7441 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
O
MeO
Cl
Br
KP-4-119-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
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Compound 19 IR 
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Compound 23 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 15 2009 Date Stamp Aug 15 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-82-FRAC1.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 24 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 54.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
MeO
O
ClSi
Br
OH
KP-4-82-FRAC1
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
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6.0010.273.400.910.97
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Compound 23 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  7 2009 Date Stamp Oct  7 2009
File Name C:\USERS\KESHAR\KP-4-115-FR2-Carbon Frequency (MHz) 100.53
Nucleus 13C Number of Transients 2112 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.9160 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OHMeO
Br
Cl
O
Si
KP-4-115-FR2-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
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Compound 4 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Oct  1 2009
Date Stamp Oct  1 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-PARADIPHENOL.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 16 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
MeO
Cl
Br
KP-5-PARADIPHENOL
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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Compound 4 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Oct  8 2009 Date Stamp Oct  8 2009
File Name C:\USERS\BOOK 6\KP-LI6-C13-DIPHENOL.FID\FID
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 3680 Original Points Count 18720
Points Count 32768 Pulse Sequence s2pul Receiver Gain 40.00 Solvent DMSO-d6
Spectrum Offset (Hz) 4915.7617 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT 
TEMPERATURE
OH
OH
MeO
Cl
Br
KP-LI6-C13-DIPHENOL
220 200 180 160 140 120 100 80 60 40 20 0 -20
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Compound 4 IR 
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Compound 2 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Jul 19 2007
Date Stamp Jul 19 2007 File Name C:\USERS\KESHAR\KP-4-22-Proton
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent Acetone
Spectrum Offset (Hz) 999.5056 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
CHO
KP-4-22-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
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0.901.001.00
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Compound 2 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Aug  1 2007 Date Stamp Aug  1 2007
File Name C:\USERS\KESHAR\KP-4-22-Carbon Frequency (MHz) 50.29
Nucleus 13C Number of Transients 11897 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent Acetone Spectrum Offset (Hz) 4962.9824
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
CHOOH
OH
Cl
KP-4-22-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 116 
Compound 24 
1
H NMR 
 
  
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Jul 20 2007
Date Stamp Jul 20 2007 File Name C:\USERS\KESHAR\DESKTOP\NMR\HUIPING\HZ-9-82-AC.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
CHOO
O
Cl
Si
Si
KP-4-25-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.006.0010.2410.340.880.820.88
 
 117 
Compound 24 
13
C NMR 
 
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Aug  2 09
Date Stamp Aug  2 09 File Name C:\USERS\KESHAR\DESKTOP\KP-4-25-FRAC2\FID Frequency (MHz) 100.56
Nucleus 13C Number of Transients 96 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9502.9023 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 27.000
CHO
Cl
O
Si
O
Si
KP-4-25-FRAC2
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 118 
Compound 25 
1
H NMR 
 
Acquisition Time (sec) 2.0486 Comment Std proton Date Jul 21 2007 Date Stamp Jul 21 2007
File Name C:\USERS\KESHAR\KP-5-Formate Frequency (MHz) 399.78
Nucleus 1H Number of Transients 4 Original Points Count 17199 Points Count 32768
Pulse Sequence s2pul Receiver Gain 44.00 Solvent DEUTERIUM OXIDE
Spectrum Offset (Hz) 3241.8862 Spectrum Type STANDARD Sweep Width (Hz) 8395.42 Temperature (degree C) 25.000
OCHOO
O
Cl
Si
Si
KP-5-FORMATE.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
7.347.0812.1312.481.100.951.00
 
 
 119 
Compound 25 
13
C NMR 
 
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Aug  4 09
Date Stamp Aug  4 09 File Name C:\USERS\KESHAR\DESKTOP\KP-4-FORMATE\FID Frequency (MHz) 199.9
Nucleus 13C Number of Transients 128 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9512.8496 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 25
O
Cl
OCHO
O
Si
Si
KP-4-FORMATE
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
o
rm
a
liz
e
d
 In
te
ns
ity
 
 
 120 
Compound 26 
1
H NMR  
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  2 2008
Date Stamp Aug  2 2008 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-86-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.2900 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OHO
O
Cl
Si
Si
KP-1-86-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
7.217.2513.5413.371.100.98
 
 
 
 121 
Compound 26 
13
C NMR  
 
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Jan  7 2009
Date Stamp Jan  7 2009 File Name C:\USERS\KESHAR\DESKTOP\KP-4-76-SM-C13\FID Frequency (MHz) 199.9
Nucleus 13C Number of Transients 128 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9513.0752 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 25
O
Cl
OH
O
Si
Si
KP-4-76-SM-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 122 
Compound 27 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  6 2008
Date Stamp Aug  6 2008 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-86-DPCOLUMN.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 39.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.6563 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
Cl
OH
Br
Si
Si
KP-1-86-PROTON1.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.927.0812.3911.850.851.00
 
 
 
 123 
Compound 27 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep  6 200 Date Stamp Sep  6 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-76-SM-BR\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 320 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.4648 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
Cl
OH
O
Si
Si
Br
KP-4-76-SM-BR
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
o
rm
a
li
ze
d
 In
te
ns
it
y
 
 
 
 124 
Compound 28 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Apr 21 2009
Date Stamp Apr 21 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-76-CRUDE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 100 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3816 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OMeO
O
Cl
Si
Si
Br
KP-4-76-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
6.506.549.639.483.290.97
 
 
 
 125 
Compound 28 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  8 2009 Date Stamp Oct  8 2009
File Name C:\USERS\KESHAR\KP-4-76-C13 Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1408 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.9160 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OMeO
O
Cl
Si
Si
Br
KP-4-76-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 126 
Compound 3 
1
H NMR 
 
 
 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 14 2009
Date Stamp May 14 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-91-DPPURE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
Br
OMe
KP-4-91-DPPURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.000.96
 
 127 
Compound 3 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Oct 22 2009 Date Stamp Oct 22 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-91-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 17867 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.8467 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OMeOH
OH
Cl
Br
KP-4-91-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 128 
Compound 3 IR 
 
 
 
 129 
Compound 29 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  4 2009
Date Stamp Aug  4 2009 File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-SM\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 18.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1003.0914 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
OH
Cl
CHO
Si
KP-4-97-SM
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
7.0013.231.051.090.951.00
 
 
 130 
Compound 29 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Aug 17 2009 Date Stamp Aug 17 2009
File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-SM-C13\FID
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 640 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.5117 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
OH
Cl
CHO
Si
KP-4-97-SM-C13
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 
 
 131 
Compound 30 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Sep 18 2009
Date Stamp Sep 18 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-32-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 44 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
CHOO
OMe
Cl
Si
KP-5-32-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.1912.473.310.961.060.94
 
 
 132 
Compound 30 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Aug 17 2009 Date Stamp Aug 17 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-SM-C13P\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 752 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.0840 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
CHO
Cl
O
Si
MeO
KP-4-97-SM-C13P
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 133 
Compound 31 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 27 2007
Date Stamp Aug 27 2007 File Name C:\USERS\KESHAR\KP-4-97-Fr1-Proton
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3890 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
OCHO
Si
KP-4-97-FR1-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.1610.813.331.090.991.08
 
 
 
 
 134 
Compound 31 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep  1 2009 Date Stamp Sep  1 2009
File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-FR-1-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 12208 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d Spectrum Offset (Hz) 4881.2285
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
OCHO
Si
KP-4-97-FR-1-C13
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 
 135 
Compound 32 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 27 2009
Date Stamp Aug 27 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-FR2\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.6563 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
Si
OH
KP-4-97-FR2
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
5.9811.513.410.850.870.81
 
 
 
 136 
Compound 32 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Aug 29 2009 Date Stamp Aug 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-FRAC2-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1856 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10557.2520 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
MeO
Cl
Si
OH
KP-4-97-FRAC2-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 
 137 
Compound 33 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 26 2009 Date Stamp Aug 26 2009
File Name C:\USERS\KESHAR\KP-5-11-FR1-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 44 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
O
MeO
Cl
OH
Br
Si
KP-5-11-FR1-PROTON.ESP
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.0010.143.200.930.98
 
 
 
 138 
Compound 33 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Sep  4 2009 Date Stamp Sep  4 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-5-19-SM-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 15226 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10555.8564 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
Cl
O
Si
MeO Br
KP-5-19-SM-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 139 
Compound 5 
1
H NMR  
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 27 2009 Date Stamp Aug 27 2009
File Name C:\USERS\KESHAR\KP-5-19-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 20 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 42.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OHOH
MeO
Cl
Br
KP-5-19-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.000.89
 
 
 
 140 
Compound 5 
13
C NMR 
  
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct 23 2009 Date Stamp Oct 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-5-19-DP-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 5696 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.3848 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
Cl
OH
MeO Br
KP-5-19-DP-C13
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 141 
Compound 5 IR 
 
 
 142 
Compound 35 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 19 2009
Date Stamp May 19 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-95-CRUDE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3890 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
Cl
Br
OH
KP-4-95-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
2.442.551.1010.10
 
 
 
 143 
Compound 35 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Jul  8 2009
Date Stamp Jul  8 2009 File Name E:\KESHAR NMR REMAIN\SR-10-96-PURE-13C.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 1872 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4878.5532 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
O
OH
Br
Cl
SR-10-96-PURE-13C
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 144 
Compound 6 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jul  7 2009 Date Stamp Jul  7 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-5-13-CRUDE\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 4 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 46.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OHOH
OH
Cl
Br
KP-5-13-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
0.820.890.850.89
 
 
 145 
Compound 6 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Jul 22 2009 Date Stamp Jul 22 2009
File Name E:\KESHAR NMR REMAIN\SR-10-97-REPEAT-C13-METHANOL-D4.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 7048 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent METHANOL-d4 Spectrum Offset (Hz) 4978.7695
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
OH
Br
Cl
SR-10-97-REPEAT-C13-METHANOL-D4
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.009
0.010
0.011
0.012
0.013
0.014
0.015
0.016
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 146 
Compound 6 IR 
 
 
 
 
 
 147 
Compound 7 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jun  2 2008 Date Stamp Jun  2 2008
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-1-16-FRAC-13-29.FID\FID Frequency (MHz) 399.76
Nucleus 1H Number of Transients 32 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 50.00 Solvent DEUTERIUM OXIDE
Spectrum Offset (Hz) 2455.7793 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
CH2OH
OH
NH2
KP-1-16-FRAC-13-29
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 In
te
ns
ity
2.081.031.010.89
 
 
 
 148 
Compound 7 
13
C NMR 
 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 17 2009 Date Stamp Jul 17 2009
File Name C:\USERS\KESHAR\KP-1-16-FR2-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 26396 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent DMSO-d6 Spectrum Offset (Hz) 10486.7480
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
CH2OH
OH
NH2
KP-1-16-FR2-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 149 
Compound 7 IR 
 
 
 
 
 150 
Compound 8 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jun  2 2008 Date Stamp Jun  2 2008
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-16-FRAC-4-9.FID\FID Frequency (MHz) 399.76
Nucleus 1H Number of Transients 32 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 56.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2418.0771 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
CH
3
NH
2
OH
KP-1-16-FRAC-4-9
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.261.000.921.07
 
 
 
 151 
Compound 8 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std Carbon experiment Date Jun 28 2012
Date Stamp Jun 28 2012 File Name C:\USERS\KESHAR\DESKTOP\KP-1-16-FRAC1-C13.FID\FID
Frequency (MHz) 100.58 Nucleus 13C Number of Transients 1664 Original Points Count 31413
Points Count 32768 Pulse Sequence s2pul Receiver Gain 20.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10556.1475 Spectrum Type STANDARD Sweep Width (Hz) 24154.59 Temperature (degree C) 25.000
CH3
NH2
OH
KP-1-16-FRAC1-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 152 
Compound 8 IR 
 
 
 
 
 153 
Compound 10 
1
H NMR  
 
 
 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Nov 16 2009
Date Stamp Nov 16 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-72-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
KP-5-72-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
or
m
al
iz
ed
 In
te
ns
ity
6.5018.030.850.821.86
 
 154 
Compound 10 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE
KP-5-72-Dp-C13 Date Nov 18 2009
Date Stamp Nov 18 2009 File Name C:\USERS\KESHAR\KP-5-72-Carbon
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 384 Original Points Count 18720
Points Count 32768 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4878.5537 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
KP-5-72-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 
 155 
Compound 11 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Nov 17 2009
Date Stamp Nov 17 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-73-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 96 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 18.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.7551 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
Br
KP-5-73-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
18.306.320.992.00
 
 
 
 
 156 
Compound 11 
13
C NMR 
 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Nov 18 2009 Date Stamp Nov 18 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-73-DP-C13.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 416 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4879.3164 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
Br
KP-5-73-CARBON.ESP
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 157 
Compound 12 
1
H NMR  
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-77-CRUDE.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 8 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 48.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2404.7087 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
OH
KP-5-77-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.0717.362.131.142.00
 
 
 
 
 158 
Compound 12 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-77-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 512 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10550.8555 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
OH
KP-5-77-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 
 159 
Compound 13 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 24 2009 Date Stamp Nov 24 2009
File Name C:\USERS\KESHAR\DESKTOP\KESHAR NEW NMR BACKUP 2011\NMR BACK UP 4 AND 5\KP-5-78-DP.FID\FID
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 4 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 36.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2405.0991 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
O
H
KP-5-78-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
24.000.941.920.83
 
 
 
 160 
Compound 13 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 24 2009 Date Stamp Nov 24 2009
File Name C:\USERS\KESHAR\DOCUMENTS\KESHAR NMR\KESHAR\COPY OF KESHAR NOVA 3-16-2011\KESHAR\KP-5-78-C13.FID\FID
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 448 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
O
H
KP-5-78-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 161 
Compound 13 IR 
 
 
 
 
 162 
Compound 15 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\KP-5-69-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 16 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2405.0991 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
N
H
OH
KP-5-69-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
19.186.451.052.170.990.95
 
 
 
 163 
Compound 15 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\KP-5-69-Carbon
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 544 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
N
H
OH
KP-5-69-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 164 
Compound 15 IR 
 
 
 
 
 165 
Compound 16 
1
H NMR  
 
  
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 29 2009 Date Stamp Nov 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-81-FRAC2.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 20 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2454.6799 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
NH
KP-5-81-FRAC2
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
7.0019.202.142.121.085.21
 
 166 
Compound 16 
13
C NMR 
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 29 2009 Date Stamp Nov 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-81-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1000 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10550.1191 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
NH
KP-5-81-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 167 
Compound 17 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-42-FRAC2-PURE.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 16 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
KP-5-42-FRAC2-PURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
9.769.493.002.871.980.910.970.900.93
 
 
 
 168 
Compound 17 
13
C NMR  
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name E:\KESHAR NMR REMAIN\KP-5-42-FRAC2.FID\FID Frequency (MHz) 100.53 Nucleus 13C
Number of Transients 512 Original Points Count 31375 Points Count 32768 Pulse Sequence s2pul
Receiver Gain 30.00 Solvent CHLOROFORM-d Spectrum Offset (Hz) 10550.8555
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
KP-5-42-FRAC2
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
 
 169 
Compound 18 
1
H NMR 
 
Acquisition Time (sec) 2.0487 Comment KP-5-85-frac19 Date Dec  3 2009
Date Stamp Dec  3 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-85-FRAC19.FID\FID
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 28 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 42.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2404.7219 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
O
KP-5-85-FRAC19
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
9.006.089.122.032.030.910.97
 
 
 170 
Compound 18 
13
C NMR  
 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-76-FRAC7-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 512 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
KP-5-76-FRAC7-C13
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MON-0585 (compound 9) 
1
H NMR  
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 24 2009 Date Stamp Aug 24 2009
File Name C:\USERS\KESHAR\KP-5-15-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 40 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 36.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2397.2451 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
KP-5-15-FRAC1-PROTON.ESP
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18.006.310.961.904.09
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Compound 52 
1
H NMR 
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Compound 53 
1
H NMR 
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Compound 54 
1
H NMR 
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Compound 54 
13
C NMR 
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Compound 56 
1
H NMR 
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Compound 57 
1
H NMR 
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Compound 58 
1
H NMR 
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Compound 59 
1
H NMR 
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Compound 59 MS 
 
 
